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3 Abstract 
Background 
     Diabetes is characterized by high blood sugar, or hyperglycemia. In addition to diet 
and exercise, several classes of medications are commonly used to treat hyperglycemia in 
type 2 diabetes in an attempt to reduce the downstream micro- and macrovascular 
complications of the disease. Four large trials showed few benefits and significant harms 
from attempting to achieve near normal glycemic control in middle aged people with type 
2 diabetes. Benefits of aggressive glycemic control are further reduced for older adults 
with longstanding disease, those who have accumulated many of the complications of 
diabetes, and people with other comorbid conditions that limit life expectancy. This more 
complex older adult population is also at greater risk of iatrogenic hypoglycemia, a harm 
associated with treatment. For these reasons the American Diabetes Association and the 
American Geriatric Society have published guidelines recommending less stringent 
glycemic control for older adults with multiple comorbid conditions and limited life 
expectancies. However, little is known about how these guidelines are being 
implemented by primary care clinicians who provide most of the chronic disease 
management in the US. 
Methods 
     A factorial vignette study was used to determine the effect of the patient 
characteristics mentioned in the existing guidelines on a clinician’s decision to prescribe 
a second-line treatment to achieve tighter glycemic control. The factors varied were 
patient age / disease duration (65 with short disease duration, 80 with long disease 
duration), cardiovascular disease (no heart disease, coronary artery disease with previous 
bypass), and cognitive impairment (no impairment, cognitive impairment that restricted 
ability to drive). Two policy-relevant glycated hemoglobin (HbA1c) levels were varied in 
the vignettes: 7.5% or 8.5%. Independent and combined effects of patient factors (patient 
complexity) were considered. Primary care clinicians from around the US were asked to 
participate via email. Clinician information was collected, including: years in practice, 
familiarity with treating older adults, and clinician type (family, internal, nurse 
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practitioner). Clinicians were also asked to predict how likely the hypothetical patient 
was to adhere to their medication choices. Mixed effect models were used to account for 
the panel nature of the data (clinicians viewing multiple vignettes).   
Results 
     366 primary care clinicians from 36 states participated, with the majority of 
respondents practicing in Minnesota (35% of sample) or Florida (26% of sample). While 
we found some sensitivity to the patient factors mentioned in the existing guidelines, we 
also found evidence of overtreatment of the most complex hypothetical patients. For 
example, an 80-year-old with longstanding diabetes, cognitive impairment, and coronary 
artery disease requiring bypass had a second-line treatment added 35% of the time at a 
HbA1c level of 7.5%, and 75% of the time at a HbA1c of 8.5%. The same patient was 
recommended a sulfonylurea or insulin (agents known to increase the risk of iatrogenic 
hypoglycemia) 36% of the time at a HbA1c level of 7.5% and 44% of the time at a 
HbA1c level of 8.5%. Family practice physicians were less likely to add an additional 
medication than internal medicine physicians or nurse practitioners. Clinicians did not 
incorporate their adherence predictions into their decisions to intensify medication 
therapy.  
Conclusions 
     This work is part of a larger discussion around balancing the risks and benefits of 
aggressively treating hyperglycemia in older adults with type 2 diabetes for whom tight 
glycemic control produces few benefits and significantly increases risk for iatrogenic 
hypoglycemia. Clinicians may treat more aggressively than guidelines recommend 
because they are unfamiliar with the geriatric-specific guidelines or they may work in 
settings where performance incentives are tied to achieving HbA1c levels recommended 
for average or healthier patients. As few benefits and serious harms are associated with 
overtreatment, policy recommendations include: 1. creating performance incentives to 
reduce anti-glycemic medication therapy when appropriate; and 2. developing tools to 
help primary care clinicians evaluate complexity and life expectancy in their older 
patients with multiple chronic conditions.  
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6 Introduction 
     Chronic disease accumulates with age and is a central issue in geriatric care. 
Approximately one in three people in the United States will develop diabetes, at some 
point in their lives.1 In 2012, the CDC estimated there were 21.0 million people with 
diagnosed diabetes and 8.1 million people with undiagnosed diabetes living in the United 
States, or 9.3 percent of total population; 11.2 million of these diagnosed and 
undiagnosed diabetic cases were over 65 years of age.2 Improved therapeutic remedies 
are allowing more people who are diagnosed with type 2 diabetes in middle age to live 
into older adulthood.3  
     For otherwise healthy adults with diabetes, physicians prescribe medications to 
achieve near-normal glycemic control and slow the downstream vascular complications 
associated with prolonged hyperglycemia. However, for older adults with longstanding 
diabetes, cognitive impairment, or cardiovascular complications, tight glycemic control 
can often come at the cost of increased risk of severe iatrogenic hypoglycemia.4, 5 In fact, 
hospitalization rates for hypoglycemia now exceed those for hyperglycemia in the 
Medicare population and the rates of hospitalization for hypoglycemia double for patients 
with diabetes aged 75 or older compared to patients aged 65 to 74.6 Finding a glycemic 
control “sweet spot” in older patients is complicated and a topic of debate. 
     Given the risk of severe hypoglycemia with tight glycemic control, the American 
Diabetes Association (ADA) and the American Geriatrics Society (AGS) recommend less 
stringent glycated hemoglobin (HbA1c) targets for older adults with diabetes who have 
limited life expectancy, cognitive impairment, longstanding disease, advanced 
microvascular or macrovascular complications, or multiple comorbidities.7, 8 In general, 
these guidelines ask clinicians to individualize glycemic targets for medically complex, 
older adults to simultaneously avoid the risk of severe hypoglycemia while minimizing 
the effects of persistent hyperglycemia, such as cognitive dysfunction, dehydration or 
frequent urination.7, 9 Existing recommendations also advocate for patient-centered 
glycemic targets that consider patient costs of care, patient motivation and ability to self-
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manage, and the availability of resources of a support system.10 We know very little 
about how providers apply these recommendations in practice.11  
     Most of the care received by older adult diabetics is provided by primary care 
providers,12 the vast majority of whom are generalists, not geriatricians.13 Only 23 
percent of medical schools require a course in geriatrics and two-thirds of internists do 
not believe they are adequately trained in chronic care.14 Primary care clinicians routinely 
choose between the 30 different medications from 9 unique drug classes approved for 
hyperglycemic management.15 Complex decisions that occur in natural settings rely on 
established patterns, or heuristics, in which some information is consciously or 
unconsciously ignored by the decision maker.16 Claims data and information from 
electronic medical records cannot help us understand underlying decision making 
processes. The use of factorial survey methodology is not new, but it has regained interest 
in recent years as a tool for unraveling complex medical decisions.17-21  
     Results of this factorial vignette study are presented as three short papers. The aims of 
the papers are to determine the independent and combined effects of patient HbA1c level, 
age, and presence of cognitive impairment and coronary artery disease on primary care 
clinicians’: 
     Paper 1. Decisions to intensify first-line medication therapy (Figure 1, Model 1) 
     Paper 2. Choices between existing second-line therapies (when clinicians choose to 
intensify first-line treatment) (Figure 1, Model 1) 
     Paper 3. Adherence predictions (Figure 1, Model 2) 
     Papers 1 and 2 considered two ways clinicians can decrease the risk of serious 
iatrogenic hypoglycemia in older, more complex patients, either by not intensifying anti-
glycemic medication therapy or by choosing a medication with a lower hypoglycemic 
risk profile. In Paper 3, we asked how a clinician’s adherence prediction for a 
hypothetical patient with cognitive impairment affects her decision to intensify 
medication therapy. In all three papers, we also evaluate whether the clinicians’ decisions 
vary by provider type, years of practice, length of routine visit, and familiarity with the 
Medicare population. 
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     This work is part of a larger discussion around balancing the risks and benefits of 
aggressively treating hyperglycemia in older adults with type 2 diabetes for whom tight 
glycemic control produces few benefits and significantly increases risk for severe 
iatrogenic hypoglycemia. Clinicians have long known that hypoglycemia was a 
potentially severe side effect of antidiabetic treatment. However, the magnitude of this 
harm, particularly for older adults, has gained attention in the professional press5, 22-25 and 
coincides with a growing societal discussion about how we can live meaningful, less 
medicated older lives.26, 27   
7 Background 
7.1 Diabetes in Older Adults 
     Diabetes is a group of metabolic diseases characterized by hyperglycemia, or high 
blood glucose, resulting from defects in insulin secretion, insulin action, or both. The two 
major classifications in use today, diabetes mellitus type 1 and diabetes mellitus type 2, 
were proposed by the National Diabetes Data Group in 1979 and confirmed by the World 
Health Organization in 1985.28, 29  Type 1 diabetes, formerly insulin dependent diabetes, 
accounts for only 5-10 percent of all diabetes cases; it typically results in absolute insulin 
deficiency due to the autoimmune destruction of B-cells of the pancreas.30 Type 2 
diabetes, formerly non-insulin dependent diabetes, accounts for 90-95 percent of all cases 
and is characterized by insulin resistance with relative, rather than absolute, insulin 
deficiency.30  
     This vignette study focused on a case with type 2 diabetes of middle-age onset, 
distinguished by the duration of disease which indicates an onset around age 60, and an 
elevated body mass index (BMI). We chose to focus on middle-age onset because the 
four large trials that define what we know about the effect of tight glycemic control on 
outcomes in type 2 diabetes enrolled people with middle-age onset type.9, 31, 32  
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7.2 Goals of Anti-Hyperglycemic Medication Therapy 
     The hallmark of diabetes is elevated blood sugar levels, or hyperglycemia. In addition 
to diet and exercise, there is one widely accepted first-line medication (Metformin) for 
type 2 diabetes and six classes of second-line medications available to help reduce blood 
sugar levels in people with diabetes.33 Diabetes causes significant morbidity and is a 
strong predictor of functional decline in older adults.34-36 Treatment in diabetes is focused 
on slowing the development of microvascular and macrovascular complications 
associated with high blood sugar, or hyperglycemia, while avoiding harms related to 
significant lows in blood sugar, or hypoglycemia. The term iatrogenic hypoglycemia is 
used to refer to hypoglycemia resulting from treatment. 
     The current study considered a clinician’s decision to intensify anti-hyperglycemic 
medication therapy by adding a second-line medication. In this section, we review the 
harms associated with prolonged hyperglycemia, or high blood sugar, that clinicians who 
intensify anti-hyperglycemic therapy are likely attempting to delay or prevent. 
 
7.2.1 Microvascular Complications 
     The microvascular complications of diabetes include nephropathy (kidney damage), 
neuropathy (nerve damage), and retinopathy (retinal damage). Chronic sensorimotor 
neuropathy, (often characterized by patients as a tingling, pins-and-needles pain or 
numbness in extremities), is the most common microvascular complication in diabetes, 
occurring in over half of people with long-standing diabetes.37 Careful monitoring and 
early treatment of neuropathic complications, including foot ulcerations, may help avoid 
late sequelae, including potential amputation.37-39 Unfortunately, the reduced mobility 
and visual impairment of older subjects hampers their ability to inspect their feet, which 
is a fundamental component of diabetic foot care.40, 41 Once foot abnormality is 
established, it leads to significant morbidity and mortality, which is accentuated in elderly 
diabetic patients. Compared to elderly people without diabetes, people with diabetes are 
1.5 times more likely to have poor eyesight or blindness.42 Approximately 40 percent of 
people with longstanding diabetes develop diabetic retinopathy.42 Diabetic kidney 
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disease, or nephropathy, occurs in 20 to 40 percent of patients with diabetes.43, 44 Twenty 
percent of those with nephropathic symptoms develop end stage renal disease (ESRD).43 
     Serious microvascular complications take a long time to develop. Aggressive 
glycemic control over an extended period (at least eight years) may slow the development 
of microvascular complications. Tighter glycemic control is more important for younger, 
otherwise healthier people with diabetes than for older people with diabetes and other 
conditions that limit their time to reap microvascular benefits of tight control. 
 
7.2.2 Macrovascular complications 
     Macrovascular complications, including cardiovascular disease, stroke, and ultimately 
heart failure, are thought to be the result of narrowing of arterial walls, or 
atherosclerosis.45, 46 Diabetes is often accompanied by obesity, hypertension, and high 
cholesterol, all of which increase the risk of macrovascular complications.45 Patients with 
diabetes have an increased risk of cardiovascular disease, and are 1.5 to 4 times more 
likely to have a stroke than people without diabetes.45, 47 However, once cardiovascular 
complications are established, tight glycemic control may confer additional risk of 
cardiac death for people with longstanding type 2 disease with  low coronary artery 
calcium scores.48  
     Although researchers continue to look for the link between tight glycemic control and 
cardiac complications,49, 50 the large trials did not find this link, at least for the first ten 
years.32, 51, 52 In our vignette study, hypothetical patients either had no history of heart 
disease or had coronary artery disease that required a coronary artery bypass graft 
(CABG) one year ago. We expected clinicians to be more likely to intensify treatment for 
otherwise healthy people with diabetes and no history of heart disease to reduce 
downstream microvascular complications and, potentially, macrovascular complications, 
if the patient lives more than ten years.22  
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7.3 The Trials 
     Four large trials are the frequently cited evidence base for treating hyperglycemia in 
type 2 diabetes. It is important to review these trials in the context of the current work to 
understand the evidence on which the current guidelines were formed and the 
applicability of this evidence to specific subpopulations. Of interest in the current study, 
we sought to understand how the trial data applied to older adults with cognitive 
impairment and preexisting cardiovascular disease. 
 
7.3.1 United Kingdom Prospective Diabetes Study (UKPDS) Trial 
     Between 1977 and 1991, the United Kingdom Prospective Diabetes Study (UKPDS) 
trial enrolled 5,102 newly diagnosed type 2 diabetics and, after three months of a dietary 
intervention, non-overweight volunteers were randomized to one of three study arms: diet 
only control, intensive treatment with sulfonylureas, or intensive treatment with insulin.53 
This trial excluded those aged 65 or older at baseline.9 HbA1c target for the intensive 
treatment arms was below 7%; the diet only arm was provided medications only if 
HbA1c levels were well above 9%.53 Overweight patients were randomized to one of four 
arms: diet only control; intensive treatment with sulfonylureas; intensive treatment with 
insulin; or intensive treatment with metformin.53 Volunteers with any of the following 
characteristics were excluded: a myocardial infarction (MI) within the last year; heart 
failure; retinopathy requiring treatment; malignant hypertension; an occupation that 
prohibits insulin use; a life-limiting illness; or an “inadequate understanding” of how to 
manage their diabetes.53  
     After ten years, the average blood glucose in the diet only arm was 7.9% versus 7.0% 
in the intervention arms (medications combined).53 At ten years, there were no significant 
differences in diabetes-related or all-cause mortality between diet only and medication 
arms.53 Compared to diet alone, any medication decreased the likelihood of 
microvascular complications, primarily retinal photocoagulation; no differences in 
macrovascular complications were found.53 Hypoglycemic episodes were significantly 
greater in the medication treatment arms.53 The findings from the UKPDS trial, published 
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in 1998, focused national attention on the relative value of intensive blood pressure 
control over blood glucose control to affect morbidity and mortality in type 2 diabetes.54  
     The UKPDS trial was groundbreaking in its inability to show an association between 
glycemic control and macrovascular complications or death53  However, relevant to the 
current study, the UKPDS looked only at people with newly diagnosed diabetes who 
were less than 65 years old with no serious complications or illnesses. Given that 45 
percent of men over the age of 65 and 47 percent of women over the age of 65 have 2 or 
3 chronic diseases,55 the applicability of these results to a “typical” older adult with 
diabetes is relatively limited. This weakness was immediately recognized. Following the 
UKPDS, three large trials were conducted almost concurrently to consider the effect of 
intensive versus standard glycemic control on people with type 2 diabetes and established 
macrovascular complications.32, 51, 52 
 
7.3.2 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial 
     Beginning in 2003, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
trial enrolled middle-aged and older people (40-79, mean (±SD) of 62.2±6.8) with type 2 
diabetes at high risk for cardiovascular events.31, 51 Volunteers with the following 
histories  were deemed not eligible: hypoglycemia, a previous cardiovascular event or 
procedure within the past three months, a medical condition that limits survival (<3 
years), or factors likely to limit adherence.31 The ACCORD trial compared 
cardiovascular events in volunteers with cardiovascular risk factors randomized to either 
near-normal glycemic control (HbA1c of <6%, 6.4% median achieved) or standard 
glycemic control (HbA1c between 7% and 7.9%, 7.5% median achieved).51, 56 10,251 
volunteers from clinical research sites throughout  the US and Canada were randomized 
to the near-normal or standard glycemic treatment arms.51  
     In 2008, about 3.5 years into the trial, the ACCORD investigators were forced to 
discontinue the near-normal arm of the trial after an increase in all-cause mortality, 
cardiovascular-related deaths, and nonfatal myocardial infarctions were reported.51 The 
widely held belief that significant increases in hypoglycemic events in the near-normal 
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control arm are responsible for increased mortality has not been proven in post-hoc 
analyses.57, 58 Composite measures of microvascular outcomes, including advanced 
nephropathy or diabetic eye complications, did not differ between the intensive and 
standard control arms; incidence of albuminuria was decreased in the intensive control 
arm.59 The major contribution of the ACCORD trial was to caution providers against the 
goal of near normal glycemic control in patients with underlying cardiovascular risk 
factors. 
 
7.3.3 Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled 
Evaluation (ADVANCE) Trial 
     Between June 2001 and March 2003, the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial enrolled 11,140 
volunteers with type 2 diabetes who were at least 55 years of age (mean (±SD) of 66±6) 
with a history of major macrovascular or microvascular disease with at least one other 
risk factor for vascular disease.32 Similar to ACCORD, participants were randomized to 
intensive (HbA1c≤6.5% mean achieved) or standard glycemic control (target defined by 
local guidelines, 7.3% mean achieved) arms.32 After 5 years of follow-up, intensive 
control reduced the incidence of any major microvascular event (largest contributor being 
new or worsening nephropathy), but did not impact the incidence of any major 
macrovascular event.32 The ADVANCE trial did not find an increase in death in the 
intensively controlled arm.32 Like the UKPDS and the ACCORD trials, the ADVANCE 
trial found intensive anti-glycemic treatment was associated with an increase in severe 
hypoglycemia.32 The ADVANCE trial also reported an increase in hospitalization in the 
intensive treatment arm.32  
 
7.3.4 Veterans Affairs Diabetes Trial (VADT) 
     Finally, between December, 2000 and May, 2003, the Veterans Affairs Diabetes Trial 
(VADT) enrolled 1,791 military veterans with inadequate responses to maximum doses 
of an oral agent or insulin therapy.52 All participants had a HbA1c level >7.5%. (mean 
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(±SD) of 9.4±2 at baseline).52 At baseline, 40% of participants had a previous 
cardiovascular event, 62% had a history of microvascular complications, and 52% were 
already receiving insulin.52 The average age of participants was 60 at baseline (mean 
(±SD) of 60.3±9).52 Intensive therapy involved maximum doses of oral agents followed 
by insulin for those who were not able to achieve HbA1c levels below 6% (6.9% mean 
achieved) on oral agents alone.52 Participants in the standard therapy arms were 
administered half maximum doses, with insulin initiated only for those with HbA1c 
levels above 9% (8.4% mean achieved).52 After 5 years, no significant difference in time 
to first cardiovascular event or cardiovascular-specific death was observed between 
arms.52 All-cause mortality was not different between the two arms.52 However, in the 
intensive control arm, there were significantly more sudden deaths and a significant 
increase in the number of more serious hypoglycemic events and other harms reported.52 
The only microvascular outcome that was positively affected by intensive control was 
progression of albuminuria; no significant differences in retinopathy, major nephropathy, 
or neuropathy were observed across arms.52 Table 1 summarizes the outcomes of the 
ACCORD, ADVANCE, and VADT trials. 
     These three large trials launched a debate as to the relative benefits versus potential 
harms associated with tight glycemic control. The ADVANCE and VADT trials found 
aggressive glycemic control (<7%) in middle-aged people with diabetes and established 
macrovascular complications did not significantly reduce all-cause mortality, 
cardiovascular mortality, or macrovascular complications after five years. The ACCORD 
trial found an increase in all-cause mortality, cardiovascular-related deaths, and nonfatal 
myocardial infarctions after only 3.5 years.51 Even the positive microvascular findings 
have been brought into question as differences in the intermediate outcome of 
albuminuria have not been significantly associated with differences in the patient-
centered outcome of renal disease.60 
     However, the trials tell us virtually nothing about how to treat the older adult. Less 
than 0.5% of the ACCORD trial and 1.6% of the ADVANCE trial participants were 80 
years old or older, and, starting in 2003, the ACCORD trial excluded patients over 80 due 
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to safety concerns related to tight glycemic control.22 The existing trials highlighted the 
increased risk of hypoglycemia, particularly for older adults with longstanding disease,48, 
61 but did not provide guidance as to the optimal treatment targets for older adults with 
multiple conditions and limited life expectancy (who were largely excluded from 
participation). But, as is often the case in medicine, consensus guidelines have been 
developed to treat older adults with multiple chronic conditions, despite having very little 
or no evidence.  
 
7.4 Guidelines for Setting Anti-hyperglycemic Treatment Targets 
     The relevance of this work to policy development depends on understanding existing 
recommendations for treating older people with diabetes. The American Diabetes 
Association’s (ADA) “Standards of Medical Care in Diabetes” is a widely consumed 
position statement issued every five years, or as needed.62 The ADA’s position statement 
is peer reviewed and provides graded evidence for each clinical recommendation.62 The 
most recent update of these standards was published in 2016.7, 62-64 In general, the ADA’s 
2016 Standards of Medical Care in Diabetes recommend HbA1c targets of <6.5% to <7% 
for patients with a short disease duration and no history of severe hypoglycemia or 
cardiovascular disease (Grade A evidence for <7%, Grade C for more stringent control).65 
However, for older adults with diabetes who have limited life expectancy, cognitive 
impairment, longstanding disease, advanced microvascular or macrovascular 
complications, or multiple comorbidities, the ADA recommends less stringent targets, 
such as <8% (Grade B evidence).65 The exact language from the ADA Standards   
(Figure 2) specifically recommends less stringent glycemic targets in older adults with 
decreased autonomic responses, which allows for more effective detection and treatment 
of the early symptoms of hypoglycemia.65  
     In a separate chapter of the same guideline dedicated to the treatment of older adults, 
the standards provide more specific HbA1c targets based on cognitive and physical 
functioning, preexisting complications, and important comorbidity that limit life 
expectancy (Table 2).7 The American Geriatrics Society (AGS) has since supported the 
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three-tiered, complexity-based targets in Table 2.66 The AGS (2013) guideline 
recommends a blanket glycemic target of between 7.5% and 8% for older adults, with 
glycemic targets between 7% and 7.5% appropriate for otherwise healthy older adults, 
and glycemic targets between 8% and 9% for older adults with multiple comorbid 
conditions, poor functioning, and limited life expectancy.8 
     The current study considers how patient characteristics, mentioned in existing patient-
centered guidelines, affect primary care clinicians’ decisions to accept a certain HbA1 
level or to intensify treatment. 
 
7.5 KQ1 Relationship between Patient Vignette Characteristics and Treatment 
Intensification 
      We hypothesize glycated hemoglobin levels (HbA1c) levels, age/disease duration, 
cognitive impairment, and coronary artery disease to be related to a clinician’s decision to 
intensify treatment in the following ways. 
HbA1c 
     For this study, we systematically vary two HbA1c levels (7.5% or 8.5%) in the 
hypothetical patient vignettes. Based on the ADA guidelines65 and many quality-based 
incentive payments tied to achieving HbA1c levels below 8% for all patients, we expect 
more treatment intensification at HbA1c levels of 8.5%.  
Age 
      Increasing age is  associated with a decrease in recommended treatment 
intensification, after controlling for a host of patient and provider factors, including 
comorbidities, level of patient adherence, and number of primary care visits.67 Increasing 
age may be independently associated with non-intensification for the following reasons: 
Hypoglycemia Decreased glucose counter-regulation 68-71 results in fewer warning 
signs of hypoglycemia and an increased risk of severe or even fatal hypoglycemia 
as people age.9, 68 The UKPDS, ACCORD, ADVANCE, and VADT trials 
heightened awareness of hypoglycemic risks associated with tight control for 
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participants of all ages.32, 51-54 Post-hoc analyses showed the risk of severe 
hypoglycemic events increases with age.72, 73 
Life Expectancy Current guidelines suggest less intensive treatment for patients 
with limited life expectancy, as it takes approximately eight to ten years to realize 
the benefits of glycemic control.63, 65, 74 Primary care clinicians experience 
uncertainty estimating and applying prognosis information into clinical decision-
making.75 Based on life expectancy tables developed from the UKPDS trial, the 
estimated life expectancy of a 55 year-old man who has had type 2 diabetes for 
five years is between 13.2 years and 21.1 years (variation described only by 
baseline HDL level and smoking status).76 However, we know that life 
expectancy in older adults is quite variable, depending on important 
comorbidities, functional status, and cognition.77, 78 Prognosis support tools, such 
as ePrognosis,79 are being developed, but clinical judgement is most frequently 
used and largely inaccurate.75, 80, 81  
Disease Duration For people with type 2 diabetes of middle age onset, as age 
increases, duration of diabetes increases. Longer duration of diabetes is associated 
with more established complications and an increased likelihood of adverse 
events (including hypoglycemia) from aggressive anti-glycemic treatment.5 In the 
VADT, longstanding disease was associated with an increase in deaths in the 
intensive control arm.9 
Polypharmacy Advances in medicine help people live longer, but with multiple 
co-morbid conditions and extensive polypharmacy.82, 83 Evidence suggests the 
first anti-glycemic medication gives you the most “bang for your buck” and 
secondary treatments, meant to achieve tighter control, may results in increased 
adverse events (including unplanned hospitalizations) and drug-drug 
interactions.22, 84, 85 PCPs may accept a higher HbA1c level or reduce/discontinue 
a current anti-hyperglycemic medication as patients age to avoid these harms. 
Currently rates of appropriate de-intensification are low.86 
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     This study systematically varies two levels of patient age and disease duration in the 
vignettes: 65 years old with newly diagnosed diabetes, and 80 years old with 
longstanding disease. We expect clinicians to be less likely to intensify treatment for the 
80-year-old patient with longstanding disease. 
 
Cognitive Impairment 
     The decision to intensify anti-glycemic medication therapy for a person with cognitive 
impairment is complicated by multi-directionality in the blood glucose-cognition 
relationship. People with type 2 diabetes and cognitive impairment are more likely to 
have severe hypoglycemic events (potentially through the impaired self-management 
pathway explored in this study).4 However, people with diabetes and a history of prior 
hypoglycemic events are also at greater risk for cognitive decline and dementia than 
those without a history of hypoglycemic events.87, 88 Further, chronic high blood glucose, 
or hyperglycemia, also causes problems with cognition.89 The current recommendations 
do not support intensive control to improve cognition.7, 65 We expect for younger patients 
with short disease duration, few micro- and macrovascular complications or comorbid 
conditions, and evidence of cognitive impairment, clinicians may more aggressively treat 
hyperglycemia (particularly at 8.5%) than older patients with evidence of cognitive 
impairment and other comorbid conditions that limit life expectancy. 
 
Coronary Artery Disease with Coronary Artery Bypass Grafting (CABG) 
     Although researchers continue to look for the link between tight glycemic control and 
cardiac complications,49, 50 the large trials did not find this link.32, 51, 52 On the contrary the 
ACCORD trial found an increase in cardiac-related deaths in the intensive treatment 
arm.51, 90 Post-hoc analyses of the ACCORD and VADT suggested that tight glycemic 
control may confer additional risk of cardiac death for people with preexisting 
cardiovascular risk with longstanding type 2 disease who had low coronary artery 
calcium scores at baseline.48 One explanation for this observed relationship is through the 
pathway of repeated hypoglycemic events, which we know are increased with tight 
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glycemic control. Hypoglycemic events stress the heart.90 This stress may be 
unremarkable in otherwise healthy patients, but, in patients with coronary artery disease, 
the stress of a severe hypoglycemic event may result in acute vascular events or sudden 
death.90 The relationship between hypoglycemia and cardiovascular deaths is also 
complex and debated.48 In our vignette study, hypothetical patients either have no history 
of heart disease or have coronary artery disease that required CABG one year ago. We 
expect clinicians to be more likely to intensify treatment for the patient with no history of 
heart disease. This relationship may be modified by disease duration. 
 
7.6 KQ2 Relationship between Patient Vignette Characteristics and Anti-
glycemic Medication Choice 
     The case vignettes depicted hypothetical patients with elevated blood sugar levels 
(HbA1c levels of 7.5% or 8.5%) after three months of first-line Metformin treatment of 
1,000 mg, twice a day. As discussed in KQ1, older patients with long-standing disease, 
cognitive impairment, or cardiac complications reap fewer benefits and are at greater risk 
for adverse events from tight glycemic control. A clinician considering these risks may 
decide not to add a second-line therapy or intensify treatment (focus of KQ1) or she may 
decide to add an additional agent with a lower risk profile (KQ2).  
     Metformin, a biguanide, is the widely accepted first-line treatment for hyperglycemia 
in type 2 diabetes, primarily because it does not cause weight gain, carries no risk of 
hypoglycemia, and it is inexpensive.47, 91 Metformin primarily works by decreasing the 
amount of glucose produced by the liver, increasing insulin sensitivity. The main side 
effects of Metformin are gastrointestinal.47  
     If blood glucose, or HbA1c, targets are not met with one medication, current 
guidelines suggest adding an additional medication.33 There are 11 classes of second-line 
medication anti-glycemic therapies currently approved for use (some approved only as 
adjunct therapies).  
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This study considered the 5 most common combination (second-line) therapies: 
1. Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
2. Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
3. Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
4. Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
5. Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, 
Levemir) 
Sodium–glucose cotransporter 2 (SGLT2) inhibitors were not in widespread use when 
this study was designed and, therefore, is not offered as a second-line treatment option. 
     Second-line therapies are relatively similar in their effectiveness at reducing HbA1c 
levels.47 However, important to this study, combination therapies differ in their 
hypoglycemic risk profiles. Compared to other combination therapies, people taking 
Metformin in combination with either a second-generation sulfonylurea or long-acting 
insulin are at greater risk of hypoglycemic events. People taking Metformin and a 
sulfonylurea are almost 6 times more likely to have a mild to moderate hypoglycemic 
event than those taking Metformin and thiazolidinedione, pooled OR of 5.8 (95% CI 4.3 
to 7.7).47 People taking Metformin and a sulfonylurea were 33% more likely to have a 
hypoglycemic event compared to those taking Metformin and DPP-4.92 People taking 
Metformin and a sulfonylurea had 5 times as many hypoglycemic events as those taking 
Metformin and GLP-1 receptor agonists (5.32 versus .29 episodes per year).93 Insulin has 
the highest rate of severe iatrogenic events of all therapies for type 2 diabetes.33 Although 
sulfonylureas and insulins increase the risk of hypoglycemic events, they are the oldest 
and cheapest options for treating hyperglycemia (Table 3). The hypothetical patient in 
this study is able to afford her medications.  
     A priori, we expect clinicians who choose to intensify medication therapy by adding 
an additional medication to be more likely to choose second-line therapies with lower 
hypoglycemic risks and few side-effects (DPP-4 or GLP-1) for older patients with 
longstanding disease, cognitive impairment and coronary artery disease. 
Thiazolidinedione may increase the risk of congestive heart failure.47 We expect 
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clinicians will avoid this medication, particularly for hypothetical patients with coronary 
artery disease. 
 
7.7 KQ3 Relationship between Patient Vignette Characteristics and Clinician 
Predicted Adherence  
     Existing guidelines support the use of patient expected effort in determining 
appropriate glycemic targets, encouraging PCPs to provide less stringent HgA1c control 
to “less motivated, non-adherent” patients.10 Approximately 30 percent of diabetics are 
non-adherent to diabetic medications.94 Presence of cognitive impairment, particularly 
affecting executive and working memory, is a significant barrier to medication adherence 
in older adults.95, 96 Poor adherence may lead to harms, including hypoglycemic events, if 
a person administers an incorrect or additional dose of an anti-hyperglycemic agent, 
particularly insulin.24 
     For that reason, clinicians should not intensify treatment when they believe a patient 
will have difficulty adhering to medications.97  Existing guidelines support the use of 
patient expected effort in determining appropriate glycemic targets, encouraging PCPs to 
provide less stringent HgA1c control to “less motivated, non-adherent” patients.10 
     However, adherence information is not regularly available or obtained in practice. A 
study of audiotaped clinic visits found adherence was mentioned by either the physician 
or the patient for 62 percent of prescribed medications.98 Forty percent of adherence 
discussions were initiated by the patients and most of the physician initiated inquiries 
consisted of simply asking the patient whether she takes her medications.98 For the 
remaining 38 percent of medication decisions, adherence information is either not 
incorporated or influenced by provider adherence beliefs or predictions.  This study is 
among the first to quantify the partially mediating role of physician adherence beliefs in 
treatment intensification for diabetics with hyperglycemia. 
     A priori, we expect clinicians to predict worse adherence for hypothetical patients 
with cognitive impairment. We do not expect being older or having coronary artery 
disease to affect adherence beliefs. People with diabetes and an additional comorbid 
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condition have better adherence than those with diabetes alone,99 and patients under 60 
years old had poorer adherence than their older counterparts.100  
 
7.8 Provider Factors 
      A cohort study of federal employees with managed care in Maryland did not find 
correlation between provider factors (physician specialty, year of graduation from 
medical school, and physician gender) and the decision to intensify therapy (p>.05 for all 
factors).101 This study is consistent with a HealthPartners Medical Group study in which 
physician age, gender, specialty, and size of diabetes panel did not predict variation in 
HbA1c levels.102 Based on these studies, we do not have any reason to think that provider 
specialty (internal medicine, family practice, or nurse practitioner), length of routine 
appointment, or years in practice will influence the decision to intensify medication 
therapy, but we will examine differences by these commonly assessed variables. 
     The current study also considers the approximate percent of a clinician’s practice that 
is Medicare (<25%, 25%-74%, ≥75%). We expect clinicians who report serving a higher 
percentage of Medicare patients will be more familiar with geriatric-specific 
recommendations for setting more lenient targets based on complexity and choosing 
medication that reduce hypoglycemic risk.63 Clinicians who serve a greater percentage of 
older patients may also have developed more sophisticated algorithms to assess likely 
adherence.   
     The survey design, with clinicians viewing multiple vignettes, allows us to look at 
persistent choices and cluster effects. An example of a persistent choice is a clinician 
respondent that chooses the same medication choice for all four vignettes. Cluster effects 
are described using the intra-class correlation coefficient (ICC). The ICC describes the 
proportion of the total variance in an outcome (e.g. decision to intensify treatment) that is 
attributable to individual respondent characteristics.  
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8 The Survey 
 
8.1 Designing Factorial Vignettes 
     This study used factorial survey methodology to analyze physician decision making. 
The aim of vignettes is to make explicit or standardize the information respondents use to 
come to a decision. Survey respondents are presented a systematically constructed 
scenario, or vignette, and asked to rate the vignette on a pre-specified dimension. In this 
case, respondents will be asked what anti-hyperglycemic treatment option they are most 
likely to recommend (Aim1 and Aim 2), and how adherent the patient is likely to be to 
the recommended treatment (Aim 3). 
     The patient factors varied in this study were chosen because they correspond with the 
ADA’s recommendations for older adults with type 2 diabetes.63, 65 The following patient 
factors were used to construct the vignettes (dimension levels provided in brackets): 
HbA1c (7.5%, 8.5%); age/disease duration (65 year-old with diabetes for 5 years, 80 
year-old with diabetes for 15 years); cognitive impairment (no information, some recent 
memory loss on formal testing/depends on daughter to pay bills/stopped driving because 
she got lost); heart disease (no history of cardiovascular disease, coronary disease with 
coronary bypass 5 years ago). Table 4 presents the vignette factors and levels. 16 unique 
vignettes exist in the factorial population: 24. The factors listed in Table 4 were 
systematically varied over a base vignette as follows: 
Base Vignette: Mrs. Brown is [AGE] years old and has had type 2 diabetes for 
[DISEASE DURATION]. Three months ago, Mrs. Brown was prescribed Metformin 
1000 mg (BID), an ACE inhibitor to control comorbid hypertension, and a low-dose 
aspirin. Mrs. Brown currently has a HbA1c of [HbA1c], a BP of 140/80 mmHg, and a 
BMI of 29. Her basic metabolic profile is normal and GFR > 60. Mrs. Brown has 
[CARDIOVASCULAR HISTORY]. Mrs. Brown reports an intermittent pain in her 
feet, but has difficulty localizing it. There is no history of depression. [MEMORY 
LOSS] Mrs. Brown is able to afford her medications. 
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Base Vignette with Factors (Level 2): Mrs. Brown is 80 years old and has had type 2 
diabetes for 15 years. Three months ago, Mrs. Brown was prescribed Metformin 1000 
mg (BID), an ACE inhibitor to control comorbid hypertension, and a low-dose aspirin. 
Mrs. Brown has a HbA1c of 7.5%, a BP of 140/80 mmHg, and a BMI of 29. Her basic 
metabolic profile is normal and GFR > 60. Mrs. Brown has coronary artery disease, 
for which she underwent a coronary artery bypass graft five years ago. Mrs. Brown 
reports an intermittent pain in her feet, but has difficulty localizing it. There is no 
history of depression. Mrs. Brown has some recent memory loss on formal testing. 
She lives independently, but depends on her eldest daughter to keep her medical 
appointments and pay her bills. She stopped driving, in part because she occasionally 
got lost. Mrs. Brown is able to afford her medications. 
 
     Each respondent viewed four vignettes. The following surnames were used in the 
same order for each survey: Williams, Johnson, Jones, and Brown. These names were 
chosen because they are common surnames for black and white people in the United 
States. All hypothetical patients were female. In response to the vignette, providers were 
asked:  
1. To choose the treatment option they are most likely to recommend (Continue 
Metformin monotherapy, Metformin and Sulfonylurea, Metformin and 
Thiazolidinedione (TZD), Metformin and a DPP-4 Inhibitor, Metformin and a 
GLP-1 Receptor Agonist, and Metformin and Long-Acting Insulin); and  
2. To determine how adherent the patient is likely to be to her recommended 
medications (very unlikely to adhere, somewhat unlikely to adhere, somewhat 
likely to adhere, very likely to adhere) 
     Additional provider specific information was collected including year clinician 
finished professional education (year reported), specialty type (family medicine, internal 
medicine, nurse practitioner), average length of patient visit (reported in minutes), and 
percent of practice that is Medicare (<25%, 25%-74%, ≥75). At the end of the survey, 
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respondents were invited to provide information about how anti-hyperglycemic decisions 
were made in practice using an open text field. 
 
8.2 Target Population, Sample Frame, and Sample Size  
     The target population was primary care clinicians who actively provide primary care at 
least 75% of the time. This is a non-probabilistic sample. In probabilistic sampling, a 
random sample is drawn from the entire population of interest. Probabilistic sampling, 
therefore, implies the population has been enumerated and each member of the 
population has equal probability of being selected for the study sample. In contrast, 
purposeful non-probabilistic sampling, as was used in the current study, has a population 
of interest (primary care clinicians), but participants are not randomly selected from that 
population.  
     This study used AHRQ’s practice-based research networks and publicly attainable 
state licensure lists to obtain its sample. It is likely that the providers who participate in a 
voluntary research network, provide a working email at licensure, and reply to an 
unsolicited request to complete a survey are different from those who did not participate 
in some unobserved way. We expect physicians that participate may be more familiar 
with current guidelines or interested in research than those who did not. Therefore, we 
were are not able to generalize to the entire population of primary care physicians in the 
United States.  
     For each aim, we first conducted bivariate comparisons for categorical predictors 
using the chi-square test (χ2). The unit of analysis in factorial surveys is the vignette. 336 
clinicians viewed four vignettes, resulting in 1,344 observations. With 1,344 
observations, this study is 95% powered to find a 10% absolute difference between two 
groups [χ2 (1, N=1344)=3.84, p=.05].  
     However, these observations were not independent because each clinician respondent 
viewed more than four vignettes, leading to nested or hierarchical data. To estimate 
sample sizes for hierarchical models, we used simulation. For each aim, we: 
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1. Generated a data set with the appropriate number of predictor variables and 
variable groups 
2. Generated the outcome variable(s), yij, based on what the literature suggested was 
the relative importance of each predictor for that outcome.  
3. Made an assumption as to the total variation in the decision or prediction of 
interest that would be explained by our models. Taylor (2006) suggests that 
factorial surveys typically explain about 30 percent of the variance in decisions.20 
We chose a more conservative 20 percent. 
4. Ran the regression models to determine whether or not we are powered to detect a 
significant difference (p=.05) in the marginal effects for each predictor variable. 
We then bootstrap the standard errors to ensure stable estimates.  
     From these simulation studies, we determined that with 1000 observations from 300 
physician clusters, we are able to detect significant marginal effects for all proposed 
predictors and two-way interactions. 
 
8.3 Data Collection and Survey Development 
     The final survey tool was developed after carefully incorporating clinician feedback 
from two pilots. The first, in-person pilot allowed the primary investigator to interact 
with respondents to gather real-time feedback on item wording, survey structure, and 
response barriers. However, the first pilot was conducted on a clinician leadership 
population who spent more time conducting research than the average primary care 
clinician. The second pilot incorporated some significant content revisions from the first 
pilot and targeted a more typical clinician population. 
 
8.3.1 Pilots 
Medical Association Meeting 
     In Fall 2013, this survey was piloted at the annual conference of the Minnesota 
Medical Association (MMA). Protocol for this study was submitted to the University of 
Minnesota IRB Human Subjects Committee. The committee determined that the study is 
 22 
 
exempt from review under federal guidelines 45 CFR Part 46.101(b), study number 
1305E33481. 112 physicians attended the conference; 37 of which were family medicine 
or internists (eligible for participants). Of the 37 eligible physicians, 30 (81%) completed 
a questionnaire (120 vignettes, 119 with non-missing information). The PI (EM) and two 
of her colleagues located themselves at a table within a central thoroughfare inside the 
conference hotel. Conference participants, identified by the presence of a name badge, 
were approached. The researcher introduced herself as a doctoral student from the 
University of Minnesota completing a study on diabetic anti-hyperglycemic medications. 
The potential respondent was asked if s/he is a practicing primary care physician. If the 
potential respondent was a practicing primary care clinician and was willing to complete 
a five minute survey, copies of the participant consent statement and the survey tool, 
along with the researcher’s business card, were provided. The clinicians were asked to 
complete the three-page, single-sided survey using the pen and clipboard provided. The 
survey was printed using the University of Minnesota, School of Public Health letterhead 
to convey authority. Respondent names and organizations were not collected. Surveys 
were identified numerically.  
     The conference setting of our first pilot allowed us to conduct three formal “think-
alouds,” processes in which respondents verbalize their thoughts as they complete the 
survey. Through this process, we began to identify clinical issues that could frame 
ultimate results, including lack of familiarity or trust with newer medications. Physician 
respondent comments suggested  older medications work well and cost less, and the 
newer drugs may be a “drug company thing.” Also, we were questioned as to the use of 
Metformin with 80-year-old patients, with a few respondents believing that Metformin 
was contraindicated for elderly patients. This is, presumably, out of a fear of lactic 
acidosis. However, current evidence suggests the risk of Metformin-related lactic acidosis 
is quite small, particularly among older adults with adequate kidney function, and this 
risk pales in comparison to hypoglycemic risks.91, 103-105 
 
 
 23 
 
     Significant changes made to the survey as a result of the first pilot included: 
1. Lowered HbA1c levels. In the first pilot, we used highly-elevated levels (8.5%, 
9.3%, 10.1%). At these levels, 99.2% of the hypothetical vignettes had their 
treatment intensified. The final levels chosen were 7.5% and 8.5%. 
2. Provided creatinine clearance (kidney functioning) information for the 80 year-
old. In the final version of the survey, adequate glomerular filtration rate (GFR) 
was included in the static vignette information. 
Large Health System 
     In September 2014, we began working with a large Midwest health system. Over the 
next four months, we worked with our internal champion and their research center to 
modify the survey to benefit both parties. Before administering the second pilot, we 
increased the dose of Metformin from 850 mg (BID) to 1000 mg (BID) and eliminated 
the option to increase Metformin. Physicians felt that increasing Metformin may not be 
considered treatment intensification, but, instead, finishing a course of treatment. In 
Spring 2015, we collected 35 surveys (140 observations) from practicing clinicians. 
Important observations from this pilot included: 
1. We observed more variation in intensification at HbA1c of 7.5% than the values 
used in the previous pilot. However, intensification at 8.3% was 98%. 
2. Almost 25% of 80-year-olds with cognitive impairment had their treatment 
intensified with a sulfonylurea or insulin. 
8.3.2 Final Survey 
     The final survey, administered in Fall 2015, focused more specifically on the 
characteristics mentioned in the ADA guidelines for older adults. History of coronary 
artery disease was added to age and cognitive impairment in the final version of the 
survey. A sample of the final participant consent statement and survey instrument are 
provided as Appendix A. 
     To reach a larger audience, we created an electronic version of the survey using the 
survey software supported by the University of Minnesota, Qualtrics.106 Qualtrics had 
several advantages over the paper and pencil administration method used in the pilot:  
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 The software was able to randomly select four vignettes from the universe of 16 
vignettes for each survey; 
 The survey could now be shared via a common link that can be embedded in an 
email or newsletter; 
 Additional statistics were made available to the researchers including survey 
completion time and counts of incomplete surveys; and 
 We were able to maintain anonymity of participants, while tracking group-level 
deliverables for participating organizations. 
     Using contact information publicly available from the AHRQ’s practice-based 
research network (PBRN) registry (https://pbrn.ahrq.gov/pbrn-registry), we contacted 
over 40 networks that were comprised of practicing primary care clinicians. A sample 
approach email is provided as Appendix B. Six networks agreed to participate (2 
national, 4 regional) and forwarded a standardized link with an embedded email to their 
membership (Appendix C). This approach had a low yield of  10-15 respondents per 
network.  
     To increase the number of respondents, we used state licensure lists. We downloaded 
the Florida nurse practitioner and physician licensure lists from the state website 
(https://appsmqa.doh.state.fl.us/downloadnet/GeneralInformation.aspx). There was no fee 
associated with accessing Florida licensure lists. The Minnesota physician licensure list 
was accessed for a fee ($120 for Excel spreadsheet with contact information). Emails 
were available for approximately 60% of licensed physicians and nurse practitioners. 
After cleaning for specialties of interest, we sent emails to over 10,000 recipients 
(Appendix C). Emails were sent in batches from the primary investigator’s University 
email address with 500 blinded recipients per email (max allowed by Gmail). We were 
not able to easily send follow-ups using this method, as we received ‘do not contact’ 
responses from the first wave. We did not want to risk re-contacting those participants 
with a reminder email. The undeliverable rate was relatively low (between 5 and 7 
percent); email addresses provided during licensure were mostly valid. However, there is 
no research on the percent of emails provided for licensure that are actively monitored. 
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Therefore, we do not know the true denominator for either AHRQ PBRNs or the 
licensure samples. The response rate for PBRNs may be as high as 15% to 20%; the 
response rate for licensure-based samples is less than 5 percent.  
8.4 Sources of Survey Error & Limitations 
Sampling Error 
     This is a non-probabilistic sample. Our sample frame is not representative of all 
primary care physicians. Licensure lists have less sampling error than PBRNs.  
Measurement Error 
     Measurement error is the result of poorly worded survey items. Measurement error 
results in inaccurate or uninterruptable responses. This tool was designed as part of a 
survey design course and received expert review from a practicing primary care 
physician. The tool was also piloted twice and think-alouds were conducted. We feel we 
have anticipated many of the sources of measurement error in this survey. 
Nonresponse Error 
     This is the largest threat to quality in this survey.  Nonresponse error occurs when 
people who respond to the survey are different than those that do not respond. Clinicians 
who participate in PBRNs are different from those who do not participate. Clinicians who 
provide emails during licensure are different from those who do not; clinicians who 
respond to unsolicited emails to complete surveys without financial incentive are 
different than those who do not. We can only speculate on the direction of this bias. We 
hypothesize clinicians who participated are more likely to be interested in research and 
familiar with current guidelines than those who did not, biasing our results conservatively 
(less inappropriate intensification that actually exists if the full universe of clinicians 
were available). 
Coverage Error 
     Coverage error occurs when every member of the population does not have an equal 
chance of being included in the sample. In our sample, coverage error may be related to 
PBRNs in certain areas of the country being less likely to participate and licensure email 
address information not being publicly available for most states. 
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Other Limitations 
     Vignettes provide a starting point for considering physician decision making. 
However, hypothetical vignettes are not able to capture all information obtained in a 
clinical encounter, and the subtleties of this information.107 During the first, in-person 
pilot, a few clinician respondents mentioned that they have conversations to find ways to 
improve adherence in their patients, and they found it difficult to predict adherence 
without the context of those conversations provided in the vignettes. However, the 
evidence suggests these conversations do not routinely occur.98 Vignette research, while 
not devoid of social desirability bias, is more effective for assessment of clinical 
decision- making than chart review.108  
9 Analyses 
     Two different types of outcome variables were used in this study: dichotomous 
(decision to intensify, predicted adherence) and categorical (choice of anti-hyperglycemic 
medication combination). Bivariate comparisons for categorical predictors (χ2), as well 
as mixed effects probit regression (Aim 1, Aim 3) and multinomial regression models 
(Aim 2) were used to estimate the effects of patient and provider level information on the 
clinical decisions and the PCP’s prediction of likely patient medication adherence. 
     We report marginal effects. The marginal effects in probit analysis are the percentage 
point increase or decrease in the probability of outcome (yij) given a one-unit change in a 
predictor variable. For example, being 80 years old, compared to 65 years old, is 
associated with a 5 percentage point decrease in the probability of treatment 
intensification. In multinomial probit, the percentage point increase or decrease in 
probability of outcome (yij) for any given category is referenced to a base category. In 
Aim 3, the reference category is continuing Metformin monotherapy. 
     We also used regression models to account for the panel nature of the data (clinicians 
viewing multiple vignettes). To accurately determine sample size, we simulated a data set 
and ran a macro to determine the stability of significant results. The percentage of the 
time significant betas are achieved on all independent variables is the power (e.g. 80%). 
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Because the estimates from the TRIAD studies were available for age and HbA1c, we 
chose to determine our sample size based on Aim 1, the decision to intensify treatment. 
The effect sizes suggested by the literature are a 5 percentage point decrease in 
intensification based on age (50-64 vs 75-85) and a 25 percentage point increase based on 
HbA1c (7-8% versus >8%).67, 109, 110 We did not have literature to support effect sizes 
related to treatment intensification for cardiovascular disease or cognitive impairment. 
For these two factors, we chose a conservative 5 percentage points. A priori, we 
estimated that with 400 observations from 100 physician clusters, we are able to detect 
significant marginal effects for all four vignette-level variables and two provider-level 
factors. Our final sample included 1344 observations from 336 clinicians which allows us 
to look at all vignette and provider level factors and vignette-level interactions. To 
complete the simulation, we also needed to make an assumption as to the total variation 
in the decision or prediction of interest that could be explained by our models. Taylor 
(2006) suggests that factorial surveys typically explain about 30 percent of the variation 
in decisions.20 We chose a more conservative 20% of variation. What follows are the 
equations that were used for each Aim.   
 
Aim 1. Determine to what extent patient and provider factors affect a PCP’s decision to 
intensify medication treatment. 
Yij = B1(HgA1c)ij + B2(Age)ij + B3(Cogntive_Status)ij + B4(Cardiac_Complications)ij + 
B6(yrs_experience)j + B7(specialty_type)j  + B8(average_appt_length)j + B9(%_Medicare)j 
+ Uj + Eij 
Where:  
 = the likelihood of intensification for vignette i for clinician j; 
 = the value of the patient and provider characteristics for vignette i for clinician j, and 
 = the regression coefficients that show how X variables affect choice 
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Aim 2. Determine to what extent patient and provider factors affect a PCP’s choice of 
anti-hyperglycemic medication 
Yij = B1(HgA1c)ij + B2(Age)ij + B3(Cogntive_Status)ij + B4(Cardiac_Complications)ij + 
B6(yrs_experience)j + B7(specialty_type)j  + B8(average_appt_length)j + B9(%_Medicare)j 
+ Uj + Eij 
Where:  
 = the choice of anti-hyperglycemic medication combination for vignette i for clinician j; 
 = the value of the patient and provider characteristics for vignette i for clinician j, and 
 = the regression coefficients that show how X variables affect choice 
 
Aim 3. Determine to what extent patient and provider factors affect a PCP’s prediction of 
likely patient medication adherence. 
Yij = B1(HgA1c)ij + B2(Age)ij + B3(Cogntive_Status)ij + B4(Cardiac_Complications)ij + 
B6(yrs_experience)j + B7(specialty_type)j  + B8(average_appt_length)j + B9(%_Medicare)j 
+ Uj + Eij 
Where:  
 = the prediction of patient adherence for vignette i for clinician j; 
 = the value of the patient and provider characteristics for vignette i for clinician j, and 
 = the regression coefficients that show how X variables affect choice 
 
Mediation 
     Using the results from Aim 1 and Aim 3, we determined to what degree provider 
adherence predictions partially mediate the relationship between cognitive impairment 
and the decision to intensify treatment (Figure 1, Model 2). For mediation to occur, four 
things must be true:  
1. Cognitive impairment must be significantly associated with clinician predicted 
adherence;  
2. Cognitive impairment must be significantly associated with intensification in the 
absence of predicted adherence;  
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3. Clinician predicted adherence must be significantly associated with intensification; 
and  
4. The effect of cognitive impairment on intensification must become smaller in the 
presence of clinician predicted adherence.111  
In addition to observation of coefficients, mediation was formally tested using Sobel-
Goodman test. 
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10 Paper 1. Antidiabetic Treatment Intensification for Older 
Diabetics with Cognitive Impairment and Preexisting Heart 
Disease: A Factorial Vignette Study 
 
Introduction 
     For otherwise healthy adults with diabetes, physicians prescribe medications to 
achieve near-normal glycemic control and slow the downstream microvascular 
complications associated with prolonged hyperglycemia. However, in older age, the 
therapeutic window narrows substantially. For older adults with longstanding diabetes, 
cognitive impairment, or cardiovascular complications, tight glycemic control can come 
at the cost of increased risk of iatrogenic hypoglycemia, without vascular benefit.6, 112 In 
fact, hospitalization rates for hypoglycemia now exceed those for hyperglycemia in the 
Medicare population and the rates of hospitalization for hypoglycemia double for patients 
with diabetes aged 75 or older compared to patients aged 65 to 74.6 Finding a glycemic 
control “sweet spot” to minimize both the risk of hyperglycemia and hypoglycemia in 
older patients is complicated and a topic of debate. 
     In general, the American Diabetes Association’s (ADA’s) 2016 Standards of Medical 
Care in Diabetes recommend glycated hemoglobin (HbA1c) targets of <6.5% or <7% for 
patients with a short disease duration and no history of severe hypoglycemia or 
cardiovascular disease.65 However, for older adults with diabetes who have limited life 
expectancy, cognitive impairment, longstanding disease, advanced microvascular or 
macrovascular complications, or multiple comorbidities, the ADA recommends less 
stringent targets, such as <8%.65 In a separate section of the same guideline, dedicated to 
the treatment of older adults, the ADA standards provide more specific HbA1c targets 
based on cognitive and physical functioning, preexisting complications, and important 
comorbidity that limit life expectancy (Table 1.1).7 The American Geriatrics Society 
(AGS) supports the three-tiered, complexity-based targets in Table 1.1 with stricter lower 
thresholds,66 recommending a blanket glycemic target of between 7.5% and 8% for older 
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adults, with glycemic targets between 7% and 7.5% appropriate for otherwise healthy 
older adults, and glycemic targets between 8% and 9% for older adults with multiple 
comorbid conditions, poor functioning, and limited life expectancy.8 
    It is not clear how familiar the average primary care clinician is with these geriatric-
specific recommendations. Most of the care received by older adult diabetics is provided 
by primary care providers,12 the vast majority of whom are generalists, not geriatricians.13 
Complex decisions that occur in natural settings rely on established patterns, or 
heuristics, in which some information is consciously or unconsciously ignored by the 
decision maker.16 Little is known about how primary care clinicians incorporate the 
multiple patient characteristics mentioned in existing guidelines into their HbA1c 
treatment targets for older adults. The use of factorial survey methodology is a useful tool 
for unraveling complex medical decisions.17-21, 113  
     The objective of this research is to determine how patient characteristics associated 
with an increased risk of iatrogenic hypoglycemia, age/disease duration, cognitive 
impairment, and cardiovascular disease, affect a primary care clinician’s decision to 
intensify treatment by adding a second-line medication. We designed a vignette study in 
which we systematically varied these patient factors at two policy-relevant HbA1c levels: 
7.5% and 8.5%. 
Methods 
     This study used factorial survey methodology to analyze clinician decision making. 
The aim of vignettes is to make explicit and standardize the information respondents use 
to come to a decision. Survey respondents were presented a systematically constructed 
scenario, or vignette, and asked to rate the vignette on a pre-specified dimension. In this 
case, respondents were asked whether or not they would intensify medication therapy in 
response to poor glycemic control after six months of first-line, Metformin therapy.  
Vignette Design 
     Patient hemoglobin level, age/disease duration, presence of cognitive impairment, and 
history of coronary artery disease with a previous coronary artery bypass graft (CABG) 
were randomly varied in the vignettes. Each patient factor had two levels (Table 1.2), 
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yielding 16 possible vignette combinations. Patient gender, comorbid hypertension, body 
mass index, adequate glomerular filtration rate, mild neuropathic symptoms, lack of 
depression history, and medication affordability were held constant across vignettes. Five 
surnames that are common to both African Americans and White were used in an effort 
not to cue race. Each respondent viewed four, randomly selected vignettes. A sample 
vignette and the response set are provided (Figure 1.1). A priori, based on existing 
guidelines and recommendations, we expected clinicians to be most likely to intensify 
treatment for the 65-year-old, with a higher HbA1c, no cognitive impairment, and no 
history of cardiovascular disease.  
Measures 
     Treatment intensification was defined as adding any one of five classes of approved 
second-line medication therapies. For the purposes of this analysis, a dichotomous 
variable was created to indicate intensification of medication therapy. Any choice other 
than continuing Metformin monotherapy was categorized as treatment intensification. 
Sodium glucose cotransporter (SGLT) inhibitors were not in widespread use at the time 
this survey was developed and piloted, and, therefore were not part of the choice set.  
In addition to the patient characteristics that were systematically varied in the vignettes, a 
few clinician characteristics were also collected, including: year respondent finished 
professional education, average length of a routine visit (minutes), and percent of practice 
that is Medicare (<25%, 25-75%, >75%). We expected clinicians who were educated 
more recently or whose practice was predominately Medicare patients to be more familiar 
with tailored recommendations for older adults and, therefore, less likely to intensify 
medication therapy for the older patient with cognitive impairment and cardiovascular 
disease. We also investigated the effect of clinician type (family medicine physicians, 
internal medicine physicians and nurse practitioners) and routine visit length on the 
decision to intensify medication therapy.  
Data & Sample 
     Data were collected between August and December, 2015. The 366 respondents 
included attendees of a state-level professional association meeting (n=20), members of 
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AHRQ’s practice-based research networks (n=83), and primary care physicians and nurse 
practitioners emailed using state licensure lists for Minnesota and Florida (n=261). To be 
eligible, physicians and nurse practitioners had to be actively practicing primary care 
medicine at least 75% of the time. While geriatricians and specialists offer important 
perspectives on medication management for diabetics, this study focused on generalists 
and excluded specialists. Respondents attending a state professional association meeting 
completed the vignette survey in-person. Respondents from the practice-based research 
networks and those directly contacted were invited to participate by email and completed 
the survey online. All responses were collected anonymously using Qualtrics software. 
Analyses 
     The effect of vignette characteristics on the decision to intensify treatment was studied 
using  bivariate  and multivariate regression. Clinician variables were included in the 
regression models. Because clinicians viewed more than one vignette, we needed a 
regression model that would account for correlations between responses from the same 
clinician, so-called clinician cluster effects. The regression model chosen for this analysis 
was random effects probit. Vignette and clinician characteristics were entered into the 
model as fixed effects, with a random intercept for each physician.  This model allowed 
us to consider the intra-class correlation, or the amount of total variation that is 
attributable to idiosyncratic clinician effects.  One planned interaction model (differing 
effect of vignette characteristics by HbA1c) and one post-hoc interaction model (differing 
effect of vignette characteristics by clinician type) were also conducted. All analyses 
were conducted using Stata v.14.  
Results 
     366 clinicians from 36 states participated; more than half of the respondents practiced 
in either Minnesota (35% of sample) or Florida (26% of sample). 30 surveys (8% of 
respondents) were excluded based on their self-reported specialty: not provided or 
“other” (n=11), geriatric or palliative care (n=9), endocrinology or nephrology (n=10). 
Respondent characteristics for the 108 family medicine physicians, 73 internal medicine 
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physicians, and 155 nurse practitioners who completed the survey are provided in Table 
1.3.  
     Respondents completed their professional education between 1955 and 2015 (mean 
1996). Internal medicine physicians had more years on average since finishing their 
education (mean=1986). Nurse practitioners had fewer years since completion of their 
professional education (mean=2008). The length of a routine visit among responding 
clinicians varied from 5 to 90 minutes, with an average visit of 23 minutes in length. 
Average length of a routine visit was similar across clinician types. Respondents 
estimated what percentage of their practices are Medicare patients: 28% reported less 
than 25%; 20% reported greater than 75%; with the majority of respondents (52%) 
reporting between 25% and 75% of their practice consisted of Medicare patients. Nurse 
practitioners were the most likely to report having over 75% of their patient population 
enrolled in Medicare, followed by internal medicine physicians and family medicine 
physicians. 
     Table 1.4 describes intensification by vignette characteristics at HbA1c levels of 7.5% 
and 8.5%. 1,344 vignettes are included in this analysis (336 respondents, each viewing 
four vignettes). The largest driver of anti-hyperglycemic treatment intensification was 
HbA1c, with 56% of vignettes intensified for a hypothetical patient with a HbA1c of 
7.5% and 86% of vignettes intensified for a hypothetical patient with a HbA1c of 8.5%. 
As expected, treatment intensification was significantly more likely for the younger 
patient with shorter disease duration and the patient who did not have cognitive 
impairment. However, having coronary artery disease with previous CABG increased the 
likelihood of treatment intensification (compared to hypothetical patients with no history 
of heart disease).   
     We found similar effects of patient characteristics on the decision to intensify 
medication therapy using mixed effects probit regression (Table 1.5, Model 1). Holding 
other patient characteristics at mean values, having a higher HbA1c (8.5% versus 7.5%) 
increased the probability of treatment intensification by 32 percentage points. Being 80 
years old decreased the probability of treatment intensification by 21 percentage points, 
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compared to being 65 years old. Having cognitive impairment decreased the probability 
of treatment intensification by 11 percentage points. Coronary artery disease with 
previous CABG was not significantly associated with the probability of intensification, 
after holding other patient variables at means.  
     Adding clinician characteristics to the model did not change the key findings (Table 
1.5, Model 2). Compared to nurse practitioners and internal medicine physicians, family 
medicine physicians were significantly less likely to intensify medication therapy. A 
longer average visit length, a practice that is predominately experienced with Medicare 
patients or with a practitioner who has completed professional education within the last 
five years, did not significantly affect the decision to intensify treatment. However, the 
interclass correlation reveals that almost 60% of the variation in the decision to intensify 
medication therapy was due to idiosyncratic, unmeasured clinician characteristics, not the 
patient or clinician factors measured in this study.  
     We also ran two interaction models (Table 1.5, Models 3 & 4). First, as HbA1c has 
the largest effect on the decision to intensify medication therapy, we wanted to 
understand if the effect of HbA1c was constant or differed by patient characteristics. We 
found clinicians are more likely to accept a higher HbA1c for patients with cognitive 
impairment, but not for older patients or patients with coronary artery disease (Model 3). 
We also wanted to understand if family medicine physicians are less likely to intensify 
therapy for all patients or only for those patients with characteristics that may warrant 
less intensive treatment. We did not find differential intensification among family 
medicine physicians by specific patient characteristics (Model 4). 
     Using the coefficients from Table 1.5, Model 3, Figure 1.2 compares the predicted 
probability of treatment intensification, by provider type, for the least and most complex 
patient vignettes. We find an 80-year-old woman with a HbA1c level of 8.5%, coronary 
artery disease, a previous myocardial infarction, and a level of cognitive impairment that 
prohibits driving has mean predicted probability of treatment intensification of 82% (95% 
CI: 68%,96%) among nurse practitioners, 78% (95% CI: 67%,88%) among internal 
medicine physicians, and 63% (95% CI: 51%,75%) among family medicine physicians. 
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The same, medically complex woman with a HbA1c of 7.5% has mean predicted 
probability of intensification of 43% (95% CI: 35%, 51%) among nurse practitioners, 
37% (95% CI: 27%, 47%) among internal medicine physicians, and 23% (95% CI: 16%, 
30%) among family medicine physicians. 
Discussion 
     Clinicians were sensitive to individual patient factors mentioned in existing treatment 
guidelines, but results suggest overtreatment relative to existing guidelines. Clinicians 
were less likely to intensify medication therapy for an older patient with a history of 
coronary artery disease and cognitive impairment, but intensification rates were still high 
for the most complex patients: 35% of most complex patients had treatment intensified at 
HbA1c of 7.5%, 75% at HbA1c of 8.5%. This is noteworthy because evidence suggests 
outcomes for older people with diabetes are likely optimized at HbA1c levels between 
7.5% and 9.0%,114 or between 8% and 9% for a nursing-home eligible population.115 
The risk of potential overtreatment of medically complex older people with diabetes 
varied by provider type. Family medicine physicians are less likely than internal 
medicine or nurse practitioners to intensify medication treatment. However, this 
difference in intensification patterns by specialty was not sensitive to individual patient 
characteristics, including HbA1c level, age/disease duration, coronary artery disease, or 
cognitive impairment. While this conservative behavior benefits the population of interest 
in this study (older adults with multiple comorbid conditions), potential under-treatment 
of younger, healthier patients was also observed and warrants further study.  
     This study has some limitations. The most common critique of factorial vignette 
studies is external validity and various forms of response bias. Research has 
demonstrated that physician behavior in response to vignettes is a valid way to measure 
quality, comparable to the gold standard of standardized patients, and better than relying 
on chart abstraction.116 We also acknowledge that the clinicians who responded to this 
survey are different from those who did not respond in meaningful ways. However, if 
anything, we expect that clinicians who are part of practice-based research networks or 
who respond to an unsolicited invitation to participate in survey about diabetes care are 
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more likely to be familiar with existing guidelines than clinicians who did not respond. 
This would bias our results to be more conservative than if we were able to get a 
representative sample of all clinicians. This assumption seems to be substantiated by 
recent publications. Using HbA1c measures available in the National Health and 
Nutrition Examination Survey (NHANES), Lipska et al. (2015) found no significant 
differences in level of tight HbA1c control (<7%) between relatively healthy diabetics 
and older diabetics with complex or poor health (e.g. patients with end-stage renal 
disease, heart failure, or severe cognitive impairment).117 Feil et al. (2011) found more 
intensive anti-glycemic management in older veterans with dementia than in those 
without cognitive impairment.118 The magnitude of the potential overtreatment of 
hyperglycemia in this population is just beginning to be quantified, but likely exceeds 
50% for older adults with multiple comorbid conditions (overtreatment variously defined 
as actively controlled to HbA1c levels <7% or 7.5%).86, 113, 119-121 We estimate 
overtreatment, defined as treatment intensification for the most complex hypothetical 
patents with HbA1c levels of 7.5%, to be around 35%. It is likely clinicians who 
responded to this survey are more familiar with existing guidelines or research than the 
average clinician. 
     One policy option to address overtreatment may be to provide incentives for 
appropriate de-intensification86 or lower rates of hypoglycemia.122 Our findings suggest 
clinicians are much less comfortable with HbA1c values over 8%, even for patients who 
will not have time to benefit from the downstream macrovascular or microvascular 
complications associated with tighter control. Many primary care clinicians may work in 
settings where performance incentives are tied to achieving HbA1c levels under 8%, or 
even under 7%. Clinicians reported compliance with performance metrics as a barrier to 
implementing existing HbA1c recommendations for older adults.113 Altering performance 
metrics to consider harms or patient safety may be have positive effects for the elderly, 
but unintended consequences of such policies, such as boosting the market for newer, 
pricier medication needs to be carefully monitored.122 
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     However, clinicians may also be hesitant to allow for HbA1c levels between 8% and 
9% because there is very little evidence to support these recommendations. Several large 
trials have illuminated short-term harms associated with attempting to achieve near-
normal glycemic control (HbA1c of <6.5%) in older patients with cardiac 
complications,32, 51, 52, 112 but no randomized controlled trials have considered the longer-
term effects of managing patients to the less stringent HbA1c levels mentioned in the 
existing guidelines (7.5%-9%).60, 74 Randomized controlled trials are needed to consider 
the longer-term effects of managing older, medically complex patients to current 
guideline recommendations.60, 123 While we await trials comparing less conservative 
HbA1c treatment targets for older adults on patient-centered outcomes, the next best 
available study design is the prospective or retrospective cohort. Although cohort studies 
suffer from selective attrition and latent variable bias (unmeasured confounding), they 
may be useful in investigating potential linkages between intermediate outcomes often 
studied in randomized controlled trials (e.g. HbA1c control or albuminuria) and rate of 
downstream complications patients care about (e.g. death, end-stage renal disease). These 
links are generally assumed, but often not empirically supported.60 
     Finally, the current study suggests that most of the variation in the decision to 
intensify medication therapy is not related to patient factors, but idiosyncratic, 
unmeasured clinician decision-making heuristics. Primary care physician decision- 
making tools for older adults with multiple chronic conditions are needed124 and are 
currently being developed.125 The extent to which their use allows physicians to 
individualize care and reduce unnecessary treatment intensification remains to be seen, 
particularly in the face of “one-size-fits-all” performance markers.126 
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11 Paper 2. Choice of Second Line Antihyperglycemic Therapy 
for Older People with Type 2 Diabetes, Cognitive Impairment, 
and Cardiovascular Disease 
 
Introduction 
Almost ten years ago, three large trials found tight glycemic control increased the rate of 
serious iatrogenic hypoglycemic events among middle-aged people with type 2 diabetes 
and underlying cardiovascular risk factors.32, 51, 52 Studies have since shown the risk of 
hypoglycemic events requiring hospitalization now exceeds the risk of acute 
hyperglycemic events of similar severity for adults over 60 years old,5, 23 and the risk of 
serious hypoglycemic events increase with age, disease duration, cardiovascular disease, 
and sulfonylurea or insulin use.127, 128 The American Diabetes Association (ADA) and the 
American Geriatrics Society (AGS) recommend less stringent glycated hemoglobin 
(HbA1c) targets for older adults with longstanding disease, physical or cognitive 
impairments, or multiple comorbidities or important complications that limit life 
expectancy.7, 66  
     Clinicians may also choose medications to reduce the risk of iatrogenic hypoglycemia. 
Metformin, a biguanide, is the widely accepted first-line treatment for hyperglycemia in 
type 2 diabetes, primarily because it does not cause weight gain, carries a low risk of 
hypoglycemia, and it is relatively inexpensive.47, 91  
     However, important to this study, combination therapies differ in their hypoglycemic 
risk profiles. Compared to other combination therapies, people taking Metformin in 
combination with either a second-generation sulfonylurea or long-acting insulin are at 
greater risk of hypoglycemic events. People taking Metformin and a sulfonylurea are 
almost 6 times more likely to have a mild to moderate hypoglycemic event than those 
taking Metformin and thiazolidinedione, pooled OR of 5.8 (95% CI 4.3 to 7.7).47 People 
taking Metformin and a sulfonylurea were 33% more likely to have a hypoglycemic 
event compared to those taking Metformin and DPP-4.92 People taking Metformin and a 
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sulfonylurea had 5 times as many hypoglycemic events as those taking Metformin and 
GLP-1 receptor agonists (5.32 versus .29 episodes per year).93 Insulin has the highest rate 
of severe iatrogenic events of all therapies for type 2 diabetes.33 Although sulfonylureas 
and insulins increase the risk of hypoglycemic events, they are the oldest and cheapest 
options (particularly sulfonylurea) for treating hyperglycemia. Table 2.1. compares 
combination therapies (adapted from ADA (2016) Approaches to Glycemic 
Management).33 
     The objective of this research is to determine how patient characteristics associated 
with an increased risk of iatrogenic hypoglycemia, age/disease duration, cognitive 
impairment, and cardiovascular disease, affect a primary care clinician’s choice of 
second-line medication. We designed a vignette study in which we systematically varied 
these patient factors at two policy-relevant HbA1c levels: 7.5% and 8.5%. 
Methods 
     This study used factorial survey methodology to analyze clinician decision making. 
The aim of vignettes is to make explicit or standardize the information respondents use to 
come to a decision. Survey respondents were presented a systematically constructed 
scenario, or vignette, and asked to rate the vignette on a pre-specified dimension. In this 
case, respondents were asked to choose one of six, second-line combination therapies for 
the treatment of hyperglycemia in response to poor glycemic control after six months of 
first-line, Metformin therapy.  
Vignette Design 
     Patient hemoglobin level, age/disease duration, presence of cognitive impairment, and 
history of coronary artery disease with a previous coronary artery bypass graft (CABG) 
were randomly varied in the vignettes. Each patient factor had two levels (Table 2.2), 
yielding 16 possible vignette combinations. Patient gender, comorbid hypertension, body 
mass index, adequate glomerular filtration rate, mild neuropathic symptoms, lack of 
depression history, and medication affordability were held constant across vignettes. Five 
surnames that are common to both African Americans and Caucasians were used in an 
effort not to cue race or ethnicity. Each respondent viewed four, randomly selected 
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vignettes. A sample vignette and the response set are provided as Figure 2.1. A priori, we 
expected clinicians would choose second-line therapies with lower hypoglycemic risks 
and few side-effects (DPP-4 or GLP-1) for the 80-year-old with long-standing disease, 
coronary artery disease and cognitive impairment. Thiazolidinedione may increase the 
risk of congestive heart failure.47 We expected clinicians would avoid this medication, 
particularly for  patients with coronary artery disease. 
Measures 
Five choices of second-line combination therapies were provided to respondents:  
1. Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
2. Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
3. Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
4. Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
5. Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, Levemir) 
     Sodium glucose cotransporter (SGLT) 2 inhibitors were not in widespread use at the 
time this survey was developed and piloted, and, therefore were not part of the choice set.  
     In addition to the patient characteristics that were systematically varied in the 
vignettes, a few clinician characteristics were also collected, including: year respondent 
finished professional education, average length of a routine visit (minutes), and percent of 
practice that is Medicare (<25%, 25-75%, >75%). We expected clinicians who were 
educated more recently or whose practice was predominately Medicare patients to be 
more familiar with tailored recommendations for older adults and, therefore, less likely to 
choose medications for older, more complex patients that increase the risk of severe 
iatrogenic hypoglycemia (insulin and sulfonylureas) We also investigated the effects of 
clinician type (family medicine physicians, internal medicine physicians and nurse 
practitioners) and routine visit length on second-line medication choice.  
Data & Sample 
     Data was collected between August and December, 2015. The 366 respondents 
included attendees of a state-level professional association meeting (n=20), members of 
AHRQ’s practice-based research networks (n=83), and primary care physicians and nurse 
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practitioners emailed using state licensure lists for Minnesota and Florida (n=261). To be 
eligible, physicians and nurse practitioners had to be actively practicing primary care 
medicine at least 75% of the time. While geriatricians and specialists offer important 
perspectives on medication management for diabetics, this study focused on generalists 
and excluded specialists. Respondents attending a state professional association meeting 
completed the vignette survey in-person. Respondents from the practice-based research 
networks and those directly contacted were invited to participate by an email and 
completed the survey online. All responses were collected anonymously using Qualtrics 
software. 
Analyses 
     The effect of vignette characteristics on medication choice was considered bivariately 
and using multivariate regression. Clinician variables were included in the regression 
models. The regression model chosen for this analysis was multinomial probit. 
Multinomial probit regression is a good choice for this analysis because it allows for 
modeling a categorical outcome (medications) while accounting for the panel nature of 
the data (clinicians viewing more than one vignette). The limitation of this model is that it 
assumes the independence of irrelevant alternatives (IIA). This means, if you remove one 
drug choice from the set, the remaining alternatives are equally likely to be chosen. In 
Appendix 2.A., we run an alternative model (mixlogit) which allows for each clinician to 
have a unique choice set through random coefficients. This model yields similar results to 
the chosen model. Finally, we collapsed the second-line medication choices into 
medications with greater risk of iatrogenic hypoglycemia (sulfonylureas and insulin) and 
those with less risk of iatrogenic hypoglycemia (TZD, GLP, DPP-4). For this, secondary 
analysis, we used a mixed effects probit model. Vignette and clinician characteristics 
were entered into the model as fixed effects, with a random intercept for each physician. 
This model allowed us to consider the intraclass correlation, or the strength of 
idiosyncratic clinician effects (e.g. chose the same drug for all four vignettes viewed).  
All analyses were conducted using Stata v.14.  
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Results 
     366 clinicians from 36 states participated, with the majority of respondents practicing 
in Minnesota (35% of sample) or Florida (26% of sample). 366 respondents responded to 
four vignettes and were included in the initial analytic sample. 30 surveys (8% of 
respondents) were excluded because their self-reported specialty was: “other” or not 
provided (n=11), geriatric or palliative care (n=9), endocrinology or nephrology (n=10). 
While geriatricians and specialists offer important perspectives on medication 
management for diabetics, this study focused on generalists who provide most of the 
diabetes care for older adults in this country.129, 130 Respondent characteristics for the 108 
family medicine physicians, 73 internal medicine physicians, and 155 nurse practitioners 
who completed the survey are provided in Table 2.3.  
     Each clinician viewed four vignettes, yielding 1,344 observations. An additional 
second-line medication was added for 953 of the 1,344 (71% of the time). Factors 
affecting treatment intensification have been previously reported. (Paper 1) The most 
popular second-line treatments were DPP4s (35%) and second-generation sulfonylureas 
(34%), followed by long-acting insulin (13%), GLPs (10%) and TZDs (7%). Table 2.4 
shows bivariate comparison of second-line mediation choice by vignette factors. HbA1c 
and cognitive impairment appeared to affect medication choice. Hypothetical patients 
with higher HbA1c levels were more likely to receive insulin; hypothetical patients with 
cognitive impairment were less likely to receive long-acting insulin. Age and 
cardiovascular complications were not significantly related to medication choice in the 
bivariate analysis. 
     Results from the multinomial probit were similar to the bivariate analysis (Table 2.5). 
Having a HbA1 level of 8.5% compared to 7.5% increased the probability of choosing 
insulin by 6 percentage points (95% CI:1-12) and decreased the probability of choosing 
DPP4 by 7 percentage points (95% CI:1-14). Being 80 with long disease duration 
compared to 65 with shorter disease duration increased the probability of choosing DPP4 
by 9 percentage points (95% CI:2-15). Having cardiovascular disease with a previous 
coronary artery bypass graft compared to no history of cardiovascular complications had 
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no significant impact on second-line medication choice. The strongest patient effects 
were seen for cognitive impairment. Presence of cognitive impairment decreased the 
probability of choosing insulin or GLP (7 and 4 percentage points respectively), and 
increased the probability of choosing TZD or DPP4 (4 and 8 percentage points 
respectively).  
     Internal medicine clinicians were significantly more likely to choose sulfonylureas 
than nurse practitioners and family practice physicians. Clinicians finishing their 
professional education more recently were more likely to choose sulfonylureas and less 
likely to choose insulin and DPP4. No significant differences in second-line medication 
choice by length of routine visit or percent of practice that is Medicare were observed.  
Using a mixed effects probit regression, we re-estimated the model collapsing second-
line antihyperglycemic medication choices into those that increased hypoglycemic risk 
(insulin or sulfonylureas) and those with less risk of iatrogenic hypoglycemic risk (GLP, 
DPP4 or TZD). A hypothetical 80-year-old woman with longstanding diabetes, cognitive 
impairment, and coronary artery disease requiring bypass was recommended second-line 
therapy with either a second-generation sulfonylurea or long-acting insulin 45% of the 
time (95% CI: 36-51%) at a HbA1c of 8.5%, and 36% of the time (95% CI:29-44%) at a 
HbA1c of 7.5%. A hypothetical 65-year-old woman with relatively short duration 
diabetes, no cognitive impairment, and no history of heart disease had their treatment 
intensified with a sulfonylurea or insulin 58% of the time (95% CI:51-64%) at a HbA1c 
of 8.5%, and 50% of the time (95% CI:42-57%) at a HbA1c of 7.5%. Choice of insulin or 
sulfonylurea was not statistically different between otherwise healthy and the most 
complex patients in this population (Figure 2.2). 
Discussion 
     Respondents in this sample were more likely to choose DPP4, a newer drug with a 
lower reported risk of hypoglycemia, for older patients with longstanding diabetes and 
cognitive impairment. However, the probability of intensification with a sulfonylureas or 
insulin (agents known to increase the risk of iatrogenic hypoglycemia), for an 80-year 
with longstanding diabetes, cognitive impairment and a coronary artery disease requiring 
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CABG, was 36% at a HbA1c level of 7.5% and 44% at a HbA1c level of 8.5%. Further, 
the rates of intensification with one of these two medications known to increase the 
hypoglycemia is lower in the current study than has been previously observed. Feil et al. 
(2011) found providers in the VA system prescribed insulin for patients with diabetes and 
cognitive impairment at higher rates than for patients without cognitive impairment.131 
Thorpe (2015) found 75% of VA patients with tightly controlled hyperglycemia (<7%) 
were prescribed either a sulfonylurea or insulin and older patients with vascular disease 
were more likely to receive these drugs.120 
     There are likely a few reasons our findings differ from observational studies. First, the 
vignettes stated the patient could afford her medications. DPP-4 inhibitors are newer 
(entered the market in 2006) and expensive, more than $300 per month.22 Cost of 
medications is a concern for Medicare recipients with multiple chronic conditions who 
reach the Part D donut hole.132, 133 Even traditionally cheaper drugs, like insulin, have 
seen unprecedented price hikes for consumers in the past ten years (300% increase to 
consumers).134 The affordability of medications cannot be assumed in practice, as in this 
study. 
     Another way in which this research differs from practice is the focus on intensification 
versus de-intensification. Some clinicians may treat aggressively with insulin, earlier in 
the disease course, in order to alter the course of disease progression by protecting the β-
cell,135-137 although this is controversial.138 Other clinicians may treat insulin as a 
treatment of last resort, when glycemic control cannot be achieved with oral medications. 
In the current study, higher HbA1 (8.5% versus 7.5%) was independently associated with 
insulin use, and younger patients with shorter disease were more likely to have their 
treatment intensified with insulin. Whether as an aggressive early treatment or last resort, 
in practice many 80-year-olds with longstanding disease will be on insulin (unlike the 
current study in which the older patient with longstanding disease remained on first-line 
therapy). Focusing on de-intensification of insulin as a patient ages and accumulates 
more of the complications of the disease should be a focus of future research. We know 
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that de-intensification rates are low; deintensification occurs about a quarter of the time, 
even for those with very low HbA1c levels (<6.5%).86  
     The AGS publishes a list of potentially inappropriate medications to be avoided in the 
older adults population, called the Beers Criteria.139 The current list recommends against 
the use of short-acting insulins and glyburide, due to the high hypoglycemic risk. This 
study is limited in considering safer alternatives within the sulfonylurea class, as we 
combined safer alternatives, short-acting sulfonylureas (glipizide, gliclazide),140 and 
glyburide in the same response category. We also considered only long-acting insulin. 
We are, therefore, not able to distinguish between intensification with safer alternatives 
within the same class. 
     Combination therapy continues to grow in popularity,141 largely through the 
introduction of “better,” newer drugs and an emphasis on intermediate HbA1c control 
through performance metrics and existing guidelines.33 First-line treatment, Metformin, 
continues to be the cheapest and safest option. Evidence suggests the first anti-glycemic 
medication gives you the most “bang for your buck” and secondary treatments, meant to 
achieve tighter control, may result in increased adverse events (including unplanned 
hospitalizations) and drug-drug interactions.22, 84, 85 Choosing a second-line medication to 
reduce hypoglycemic risk is a secondary conversation to getting clinicians to accept 
higher HbA1c levels for more complex patients with limited life expectancy who face 
more harms and few benefits from aggressive care.
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12 Paper 3. Clinicians’ Beliefs about Adherence Do Not Affect 
their Decisions to Intensify Medication Therapy for Older 
Adults with Cognitive Impairment 
 
Background 
     For otherwise healthy adults with diabetes, physicians prescribe medications to 
achieve near-normal glycemic control and slow the downstream micro- and 
macrovascular complications associated with prolonged hyperglycemia. However, for 
older adults with longstanding diabetes tight glycemic control can often come at the cost 
of increased risk of iatrogenic hypoglycemia.6, 112 Among Medicare recipients, rates of 
hospitalization for low blood sugar, or hypoglycemia, now exceed the rates of 
hospitalization for high blood sugar, or hyperglycemia.6 Hypoglycemic related hospital 
use is costly, and affects the quality of life for older adults with diabetes.24, 142  
     People with diabetes and impaired cognition are more likely to have a hypoglycemic 
event resulting in medical care than those without impaired cognition.88, 118, 143 Cognitive 
impairment has been linked to poorer adherence among older adults.144, 145 Poor 
adherence may be linked to hypoglycemic events if a person administers an incorrect or 
additional dose of an anti-hyperglycemic agent, particularly insulin.24 For this reason, the 
American Diabetes Association (ADA) and the European Association for the Study of 
Diabetes (EASD) have recommended a patient-centered approach to hyperglycemic 
management, including setting less stringent HbA1c targets for people with type 2 
diabetes who have more difficulty adhering to their medication regimes or have 
difficulties with self-care.146 However, recent evidence suggests that older patients with 
diabetes and cognitive impairment were more tightly controlled than patients without 
cognitive impairment.118  
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     In order to improve clinician behavior, we need to understand how they are making 
decisions. Clinician adherence predictions become important because adherence 
information is not universally obtained during patient encounters. A study of audiotaped 
clinic visits found adherence was mentioned by either the physician or the patient for 62 
percent of prescribed medications.98 Forty percent of these adherence discussions were 
initiated by the patients and most of the physician initiated inquiries consisted of simply 
asking the patient whether she takes her medications.98 For the almost 40 percent of 
prescribed medications for which no adherence discussion occurs, clinicians are either 
not incorporating adherence information into their clinical decision making, or clinicians 
are substituting their own beliefs or predictions about likely patient adherence for patient-
reported adherence information. Unfortunately, physicians are not very good at predicting 
adherence. Doctors correctly predict nonadherence only 25-35 percent of the time.147, 148 
Translation of patient-centered guidelines to practice requires physicians to recognize 
patient factors associated with nonadherence, including cognitive impairment. 
     In this vignette study we consider whether or not a clinician’s belief about a patient’s 
ability to self-manage their medications affects their decision to intensify medication 
therapy for a patient with cognitive impairment (Figure 3.1). Based on existing 
guidelines, we would expect clinicians to be less likely to intensify medication therapy 
(by adding a second-line medication therapy) for a patient with cognitive impairment, in 
part because of poorer predicted adherence. 
     The aims of this factorial vignette study are threefold: 
1. To determine the degree to which patient cognitive impairment affects clinicians’ 
adherence predictions;  
2. To determine the degree to which patient cognitive impairment affects clinicians’ 
decisions to intensify therapy; and 
3. To determine whether or not adherence predictions partially mediate the decision to 
intensify anti-hyperglycemic medication therapy for people with diabetes and 
cognitive impairment. 
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     We are also able to consider differences in adherence predictions and treatment 
intensification by primary care clinician type and respondent familiarity with serving 
older, more complex patients. 
Methods 
     This study used factorial survey methodology to analyze clinician decision making. 
The aim of vignettes is to make explicit or standardize the information respondents use to 
come to a decision. Survey respondents were presented a systematically constructed 
scenario, or vignette, and asked to rate the vignette on a pre-specified dimension. In this 
case, respondents were asked to predict likely patient adherence to their medication 
recommendations and to recommend a medication therapy. 
Vignette Design 
     Patient hemoglobin level, age/disease duration, presence of cognitive impairment, and 
history of coronary artery disease with a previous coronary artery bypass graft (CABG) 
were randomly varied in the vignettes. Each patient factor had two levels (Table 3.1.), 
yielding 16 possible vignette combinations. Patient gender, comorbid hypertension, body 
mass index, adequate glomerular filtration rate, mild neuropathic symptoms, lack of 
depression history, and medication affordability were held constant across vignettes. Five 
surnames that are common to both African Americans and Caucasians were used in an 
effort not to cue race or ethnicity. Each respondent viewed four, randomly selected 
vignettes. A sample vignette and the response set are provided as Figure 3.2. A priori, we 
expected clinicians to believe patients with cognitive impairment are less likely to adhere 
to their medications and, therefore, clinicians will be less likely to add an additional 
medication for hypothetical patients with cognitive impairment. 
Measures 
     In response to each vignette, clinicians were asked to predict the likelihood of the 
hypothetical patient adhering to her medication regimen (very unlikely to adhere, 
somewhat unlikely to adhere, somewhat likely to adhere, very likely to adhere). 
However, we found only X% of clinicians predicted a patient would be very unlikely to 
adhere. For this reason, we collapsed predicted adherence from four categories (very 
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unlikely, somewhat unlikely, somewhat likely, very likely) to two categories (unlikely, 
likely).  
     Clinicians were also asked if they would intensify treatment for the hypothetical 
patient. Treatment intensification was defined as adding any one of five classes of 
approved second-line medication therapies. For the purposes of this analysis, a 
dichotomous variable was created to indicate intensification of medication therapy. Any 
choice other than continuing Metformin monotherapy was categorized as treatment 
intensification.  
     In addition to the patient characteristics that were systematically varied in the 
vignettes, a few clinician characteristics were also collected, including: year respondent 
finished professional education, average length of a routine visit (minutes), and percent of 
practice that is Medicare (<25%, 25-75%, >75%). We expected clinicians who were 
educated more recently or whose practice was predominately Medicare patients to be 
more familiar with tailored recommendations for older adults and, therefore, more likely 
to think patients with cognitive impairment would have difficulty adhering to 
medications and would be less likely to intensify therapy for those patients. We also 
investigated the effect of clinician type (family medicine physicians, internal medicine 
physicians and nurse practitioners) and routine visit length on the decision to intensify 
medication therapy.  
Data & Sample 
     Data were collected between August and December, 2015. The 366 respondents 
included attendees of a state-level professional association meeting (n=20), members of 
AHRQ’s practice-based research networks (n=83), and primary care physicians and nurse 
practitioners emailed using state licensure lists for Minnesota and Florida (n=261). To be 
eligible, physicians and nurse practitioners had to be actively practicing primary care 
medicine at least 75% of the time. While geriatricians and specialists offer important 
perspectives on medication management for diabetics, this study focused on generalists 
and excluded specialists. Respondents attending a state professional association meeting 
completed the vignette survey in-person. Respondents from the practice-based research 
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networks and those directly contacted were invited to participate by an email and 
completed the survey online. All responses were collected anonymously using Qualtrics 
software. 
Analyses 
     We used mixed effects probit regression to consider the following partial mediation 
steps established by Baron and Kenny (1986)149, 150: 
1. Cognitive impairment (X) must be significantly associated with treatment 
intensification (Y) 
2. Cognitive impairment (X) must be significantly associated with predicted adherence 
(M) 
3. Predicted adherence (M) must be significantly related to treatment intensification (Y) 
when both cognitive impairment and adherence are predictors of treatment 
intensification 
     If all three conditions are met, we used the difference of the effect of X on Y in the 
presence and absence of the mediator, or the indirect effect (c-c’ or ab in Figure 6.), 
divided by the standard error of the difference, using a normal distribution to determine 
the statistical significance of the mediation effect. 149, 151 The significance will be 
formally tested using mediation will be formally tested using Sobel-Goodman test. For 
the mixed effects models, vignette and clinician characteristics were entered into the 
model as fixed effects, with a random intercept for each physician. This model allows us 
to consider the intra-class correlation, or the strength of idiosyncratic clinician effects 
(e.g. chose somewhat adherent for all vignettes).  All analyses were conducted using 
Stata v.14.  
Results 
     108 family medicine physicians, 73 internal medicine physicians, and 155 nurse 
practitioners from 36 states participated, with the majority of respondents practicing in 
Minnesota (35% of sample) or Florida (26% of sample). Each of the 366 respondents 
responded to four vignettes and were included in the initial analytic sample. 30 surveys 
(8% of respondents) were excluded because their self-reported specialty was: “other” or 
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not provided (n=11), geriatric or palliative care (n=9), endocrinology or nephrology 
(n=10). Respondent characteristics for the 108 family medicine physicians, 73 internal 
medicine physicians, and 155 nurse practitioners who completed the survey are provided 
in Table 3.2.  
     Respondents completed their professional education (medical school for physicians) 
between 1955 and 2015 (mean 1996). Internal medicine physicians had more years on 
average since finishing medical school (mean=1986). Nurse practitioners had fewer years 
since completion of their professional education (mean=2008). The length of a routine 
visit among responding clinicians varied from 5 to 90 minutes, with an average visit of 23 
minutes in length. Average length of a routine visit was similar across clinician types. 
Respondents were also asked to estimate the percentage of their practice that is Medicare 
patients. 28% of sample, reported less than 25% percent of their practice was Medicare 
patients; 20% reported greater than 75% of their practice is Medicare; and 52% had 
between 25% and 75% of their practice consisting of Medicare patients. Nurse 
practitioners were the most likely to report having over 75% of their patient population 
enrolled in Medicare, followed by internal medicine physicians, and family medicine 
physicians. 
Predicted Adherence 
     We first considered the effects of the patient characteristics varied in the vignettes on 
clinician predicted adherence (Table 3.3). Age, presence of coronary artery disease 
(CAD) with previous CABG, and HbA1c were not significantly associated with clinician 
adherence predictions. Cognitive Impairment (CI) was the only vignette variable 
significantly associated with clinician adherence predictions. Three percent of 
hypothetical patient vignettes without cognitive impairment were predicted to be unlikely 
to adhere by clinician respondents, compared to 21% of hypothetical patient vignettes 
with cognitive impairment. However, clinicians predicted 79% of patient vignettes with 
cognitive impairment would be likely or very likely to adhere.  
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Treatment Intensification 
     Next, we considered the effect of the same patient characteristics on a clinician’s 
decision to add an additional medication, or intensify medication therapy. These results 
have been reported elsewhere (Paper 1). Briefly, clinicians were less likely to intensify 
treatment for hypothetical patients who were 80 years-old (versus 65), had cognitive 
impairment (compared to patients without cognitive impairment), or had a lower HbA1c 
(7.5% versus 8.5%). However, having coronary artery disease with previous CABG 
slightly increased the likelihood of treatment intensification, compared to hypothetical 
patients with no history of heart disease (Table 3.4). 
Mediation 
     Our bivariate results indicated that patient cognitive impairment is negatively 
associated with clinician predicted adherence and a clinician’s decision to intensify 
medication therapy. However, for predicted adherence to partially mediate the 
relationship between patient cognitive impairment and clinician decision to intensify 
medication therapy, the following criteria must be met: 
1. Cognitive impairment (X) must be significantly associated with treatment 
intensification (Y) 
2. Cognitive impairment (X) must be significantly associated with predicted 
adherence (M) 
3. Predicted adherence (M) must be significantly related to treatment intensification 
(Y) when both cognitive impairment and adherence are predictors of treatment 
intensification 
     Table 3.5. shows the mixed effects probit regression results corresponding to each of 
these criteria.  
Criteria 1. After controlling for other patient and provider characteristics, cognitive 
impairment was associated with an 11% (95% CI: 7%-14%) decrease in the likelihood 
of treatment intensification (Table 3.5, Model 1).  
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Criteria 2. After controlling for other patient and provider characteristics, cognitive 
impairment was also associated with an 18% (95% CI: 15%-22%) decrease in 
clinician predicted good adherence (Table 3.5, Model 2).  
Criteria 3. Clinician predicted good adherence is associated with a 3% (95% CI: -3%-
9%) nonsignificant increase in the probability of treatment intensification (Table 3.5, 
Model 3).  
     The direct effect of cognitive impairment on treatment intensification was a 11% 
decrease in treatment intensification (Pathway c in Figure 3.1. A.). When predicted 
adherence was added the model, the effect of cognitive impairment on treatment 
intensification was a 10% decrease in treatment intensification (Pathway c’ in Figure 
3.1.C.). Therefore, the indirect or partially mediated effect of cognitive impairment on 
treatment intensification through the pathway of predicted adherence was 1% (c-c’). 
Using the Sobel test for mediation,152 we find that although adherence predictions explain 
about 10% of the total effect of cognitive impairment on the decision to intensify therapy, 
this partial mediation effect was not statistically significant (p= .10). 
Discussion 
     Clinicians believed people with diabetes and cognitive impairment were less likely to 
adhere to their medication recommendations than people without cognitive impairment, 
and they were also less likely to intensify treatment for patients with cognitive 
impairment.  However, predicted adherence did not explain clinicians’ decisions not to 
intensify medication therapy for patients with cognitive impairment.  
     First, we acknowledge that adherence is a complex topic and we have a crude 
instrument. This paper focuses on only one potential barrier to adherence: memory-
related adherence problems. People who have cognitive impairment may forget to take 
their medication,153 or may take more medication than recommended.96 There are 
multiple other reasons people may not take their medications as prescribed, including 
education or healthy literacy,154, 155cost-related barriers,156 reluctance to change 
behaviors,157 depression,158-162 history of iatrogenic hypoglycemia,163 and vision 
problems related to reading prescription labels.164 None of these other types of 
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nonadherence are considered in this paper. Further, clinicians can improve adherence by 
providing patient education and changing the way medications are administered or dosed. 
164-168 This study is limited in that we are not able to consider education, dosing or 
administration. It is possible that clinicians were less likely to incorporate their adherence 
predictions into their decision to intensify therapy because they believed they could 
address their adherence concerns by modifying dose or providing patient education. 
We also recognize the discussion to this point over-simplifies the relationship between 
hyperglycemia and cognitive impairment. The decision to intensify anti-glycemic 
medication therapy for a person with cognitive impairment is complicated by multi-
directionality in the blood glucose-cognition relationship. People with type 2 diabetes and 
cognitive impairment are more likely to have severe hypoglycemic events (potentially 
through the impaired self-management pathway explored in this study). However, people 
with diabetes and a history of prior hypoglycemic events are also at greater risk for 
cognitive decline and dementia than those without a history of hypoglycemic events.87, 88 
Further, chronic high blood glucose, or hyperglycemia, also causes problems with 
cognition.89  
     We expected for younger patients with short disease duration, few micro- and 
macrovascular complications or comorbid conditions, and evidence of cognitive 
impairment, clinicians may more aggressively treat hyperglycemia (even with the risk of 
nonadherence). Being more aggressive earlier in the disease may reverse some of the 
cognition problems associated with hyperglycemia and slow insulin resistance. However, 
for older patients with long-standing disease who have accumulated more macrovascular 
disease and complications, as well as cognitive impairment, we expect providers’ beliefs 
about adherence to have a greater effect on glycemic targets. (Figure 3.3). For this reason, 
we conducted a post-hoc  analysis to determine whether adherence predictions had a 
stronger partial mediating effect on the decision to intensify medication therapy for older 
patients with longstanding disease. The indirect effect of predicted adherence on the 
decision to intensify therapy was the same as in the full sample (about 10% of total effect 
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of cognitive impairment on intensification), and the Sobel test for mediation was not 
significant (p =.24)  
     We are left to speculate as to why clinicians did not incorporate their adherence 
predictions into their treatment intensification decisions. It could be that clinicians had 
other, more dominant reasons for not intensifying treatment for a patient with cognitive 
impairment that were not adherence-related. The presence of cognitive impairment may 
be a strong signal of frailty.169  Clinician beliefs about the futility of further treatment or 
fears about potential harms associated with aggressive care may provide more direct 
pathways between cognitive impairment and treatment intensification than through 
predicted adherence. Beliefs about treatment risks or treatment futility were not measured 
in the current study and warrant further study. 
     Clinicians may also be uncomfortable incorporating their beliefs or predictions into 
clinical decision-making. Clinicians are trained to believe that they act “objectively,” 
without incorporating their beliefs or stereotypes into clinical decision-making.170       
     However, given half of what we do in medicine is based on inadequate evidence,171 
we should not be surprised that 35% of end-of-life spending and 12% of total US 
healthcare spending is associated with physician beliefs about doing less or more and not 
based on evidence of clinical benefit.172 Further, adherence beliefs have been shown to 
enter into clinician decision-making in the case of pay-for-performance initiatives in 
which clinicians excluded patients who were unlikely to adhere to their medication 
regimens, in order to protect their financial incentives.173 174 If clinicians are not 
comfortable explicitly incorporating their adherence beliefs into their treatment decisions, 
patient-centered guidelines that ask clinicians to incorporate a patient’s social support and 
ability to manage medications into treatment targets may be difficult for clinicians to 
implement.146 Guidelines that provide recommendations based on clinical diagnosis alone 
may be more readily implemented than those that ask clinicians to consider the context in 
which that condition affects outcomes. 
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13 Summary of Findings 
     While we found some sensitivity to the patient factors mentioned in the existing 
guidelines, we also found evidence of overtreatment of the most complex hypothetical 
patients. For example, an 80-year-old with long standing diabetes, cognitive impairment, 
and coronary artery disease requiring bypass had a second-line treatment added 35% of 
the time at HbA1c of 7.5%, and 75% of the time at HbA1c of 8.5%. The same patient 
was recommended a sulfonylureas or insulin (agents known to increase the risk of 
iatrogenic hypoglycemia) 36% of the time at a HbA1c level of 7.5% and 44% at the time 
at a HbA1c level of 8.5%. Clinicians did not incorporate their adherence predictions into 
their decisions to intensify medication therapy. We found a few differences in practice 
patterns by clinician characteristics. Family practice physicians were less likely to 
intensify treatment than internal medicine physicians or nurse practitioners. This is likely 
to benefit the most complex patients who were the focus of this study. However, patients 
with shorter disease duration may be disadvantaged by the wait and see approach. Some 
variation in medication choice by clinician type was also observed.  
Paper 1. 
     In paper 1 we considered the effects of vignette and clinician outcomes on the 
decision to intensify first-line Metformin therapy by adding an additional medication. 
HbA1c level, age / disease duration, and cognitive impairment significantly affected a 
clinicians’ decision to intensify medication therapy. Having a higher HbA1c increased 
the probability of treatment intensification by 32 percent; being older with long-standing 
disease decreased the probability of treatment intensification by 21 percent; and having 
cognitive impairment decreased the probability of treatment intensification by 11 
percentage points. Coronary artery disease with previous CABG was not significantly 
associated with the probability of intensification. The following two-way interactions 
were considered: HbA1c*age/disease duration, HbA1c*cognitive impairment, 
HbA1c*heart disease. Only the interaction between HbA1c and cognitive impairment 
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was significant; clinicians were more likely to accept a higher HbA1c for patients with 
cognitive impairment. Family medicine physicians were less likely to intensify therapy 
than nurse practitioners or internal medicine physicians. The most complex hypothetical 
patient, (an 80-year old with long diabetes duration, cognitive impairment and coronary 
artery disease), had a predicted probability of treatment intensification of 35% at HbA1c 
of 7.5% and 75% at HbA1c of 8.5%. Family medicine physicians were less likely than 
nurse practitioners or internal medicine physicians to intensify medication therapy for all 
patients. 60 percent of the variation in the decision to intensify medication therapy was 
due to individual physician behavior, not the patient factors varied in this study.  
Paper 2. 
     In paper 2 we considered the effects of vignette and clinician outcomes on the choice 
of second-line medication therapy, if a clinician chose to intensify in paper 1. Clinicians 
intensified 71 % of the time (953 out of 1,344). The most popular second-line treatments 
were DPP4s (35%) and second-generation sulfonylureas (34%), followed by long-acting 
insulin (13%), GLPs (10%) and TZDs (7%). HbA1c level, age / disease duration, and 
cognitive impairment significantly affected a clinician’s choice of second-line 
medication. Coronary artery disease with previous CABG was not significantly 
associated with the choice of medication. In general, having a higher HbA1c increased 
the probability of choosing insulin; being older with longer disease duration increased the 
probability of choosing DPP4; presence of cognitive impairment increased the probability 
of choosing TZD or DPP4 over insulin. Using an outcome of choosing a second-
generation sulfonylurea or long-acting insulin, medications known to increase the risk of 
iatrogenic hypoglycemia, we found clinicians were 10 percentage points less likely to 
choose these medications for hypothetical patients with cognitive impairment and 6 
percentage points less likely to choose these medications for older patients with longer 
disease duration. Higher HbA1c increased the likelihood of choosing insulin. The most 
complex hypothetical patient, (an 80-year old with long diabetes duration, cognitive 
impairment and coronary artery disease), had a predicted probability of having her 
treatment intensified with either a sulfonylurea or insulin of 36% at HbA1c of 7.5% and 
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50% at HbA1c of 8.5%. 80% of the variation in second-line medication choice was due 
to individual clinician behavior, not the patient factors varied in this study. Table 5 
summarizes the findings from the first two papers. 
Paper 3.  
     In paper 3 we asked whether clinician predicted adherence partially mediated the 
relationship between cognitive impairment and treatment intensification. For mediation to 
occur: 1. Cognitive impairment (X) must be significantly related to treatment 
intensification (Y); 2. Cognitive impairment (X) must be significantly associated with 
predicted adherence (mediator); and 3. Predicted adherence (M) must be significantly 
associated with treatment intensification. Conditions 1.and 2. were met, but condition 3. 
was not met. Clinicians believe patients with cognitive impairment are less likely than 
patients without cognitive impairment to adhere to their medications and clinicians are 
less likely to intensify medication therapy for hypothetical patients with cognitive 
impairment. However, clinicians’ beliefs about likely patient adherence do not formally 
mediate their decisions to intensify medication therapy. Further, clinicians predicted 
patients with cognitive impairment were likely to adhere over 75% of the time. Clinicians 
may not be comfortable or accustomed to incorporating adherence predications into 
treatment decisions, or cognitive impairment may affect clinicians’ decisions to intensify 
treatment through other pathways including perceived frailty. As primary care clinicians 
do not routinely discuss adherence with patients, guidelines that recommend clinicians 
consider a patient’s ability to self-manage may be under-implemented.  
14 Discussion and Implications 
     This work is part of a larger discussion around balancing the risks and benefits of 
aggressively treating hyperglycemia in older adults with type 2 diabetes for whom tight 
glycemic control produces few benefits and significantly increases risk for severe 
iatrogenic hypoglycemia. Clinicians have long known that hypoglycemia was a 
potentially severe side effect of antidiabetic treatment. However, the magnitude of this 
harm, particularly for older adults, has gained attention in the professional press5, 22-25 and 
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coincides with a growing societal discussion about how we can live meaningful, less 
over-medicated older lives.26, 27 
     The magnitude of the potential overtreatment of hyperglycemia in this population is 
just beginning to be quantified, but likely exceeds 50% for older adults with multiple 
comorbid conditions (overtreatment variedly defined as actively controlled to HbA1c 
levels <7% or 7.5%).86, 113, 119-121 We estimate overtreatment, defined as treatment 
intensification for the most complex hypothetical patents with HbA1c levels of 7.5%, to 
be around 35%. Our findings are directly aligned with a recent survey that found a third 
of primary care clinicians thought it would be difficult to follow the Choosing Wisely 
HbA1c recommendation for older adults, which states “Avoid using medications other 
than metformin to achieve hemoglobin A1c<7.5% in most older adults; moderate control 
is generally better.”113  
     There are several reasons why clinicians may be over-treating this population and/or 
report having difficulty complying with existing guidelines. One barrier often described 
by physicians is the need to comply with existing performance metrics or pay-for-
performance initiatives.113 Pay for performance incentives, rewarding intermediate 
outcomes (HbA1c levels) below a certain threshold (e.g. <8%), are in wide-spread use.175 
There is some evidence that such incentives lead to over-testing or overtreatment,176 
which may be particularly harmful to older adults with multiple comorbid conditions. 
Another barrier to clinicians complying with existing guidelines is the fear of potential 
litigation  in response to appropriate deintensification, or reducing medication burden as a 
person develops additional comorbid complications that limit life expectancy.113 
Education may be another barrier to appropriate treatment. There is a genuine lack of 
knowledge around the harms of overtreatment; 45% of primary care clinicians said they 
would not worry about potential harms from tight control (HbA1c of 6.5%) for a 77-year-
old with longstanding type 2 diabetes with severe kidney disease taking glipizide 
(sulfonylurea).113  Finally, the influence of the pharmaceutical market in overtreatment of 
hyperglycemia cannot be ignored. Profits from diabetes drugs grow by double digits 
every year based, in part, on the introduction of newer, “better” drugs and the more 
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aggressive treatment of hyperglycemia with two-drug combinations.190 The associations 
setting guidelines are not independent from the pharmaceutical companies. 
Pharmaceutical companies are the largest corporate contributors to the ADA.191 
     Several policy options / approaches to reducing overtreatment have been proposed. 
Researchers from the University of Michigan, led by Jeremy Sussman, have focused on 
opportunities around de-intensification.86 Intensive treatment is more appropriate early in 
the disease. As people age and accumulate more diabetes and other complications, it is 
likely that de-intensification should become a focus of diabetic care. However, currently, 
de-intensification occurs about a quarter of the time, even for those with very low HbA1c 
levels (<6.5%).86 A policy option may be to provide incentives for appropriate de-
intensification.86 Incentives may also be provided for lower rates of iatrogenic 
hypoglycemia.122 However, just as the current performance metrics have unintended 
consequences (potentially increased hypoglycemia in older, more complex patients), 
creating new metrics to reduce this harm may also have unintended consequences, 
including promoting the use of newer, more expensive drugs and devices.122 Further, 
quality metrics targeting a reduction in iatrogenic hypoglycemia should not replace the 
need for quality metrics targeting hyperglycemia, as that could potentially result in an 
increase in under-treatment.  
     Another, not mutually exclusive, policy approach is to create guidelines that better 
address comorbidity. For older adults, one problem with tying pay-for-performance 
incentives to intermediate outcome measures for each chronic disease is older adults have 
multiple chronic diseases. 45% of men over the age of 65 have 2 or 3 chronic diseases; 
17% have 4 or more chronic diseases.55 47% of women over the age of 65 have 2 or 3 
chronic diseases; 16% have 4 or more chronic diseases.55 For older adults with multiple 
comorbid conditions, these “one-size-fits-all” performance measures can result in 
polypharmacy and overtreatment.177-181 The AGS and others have supported efforts to 
create recommendations to address multiple comorbid conditions,125, 182-188 although there 
is little evidence on which to base these recommendations.189 Medicare policy has the 
greatest ability to affect change in how multiple, disease-specific guidelines are applied 
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to complex populations. It remains to be seen whether the newest changes to Medicare 
reimbursement through the Medicare Access and CHIP Reauthorization Act (MACRA) 
will reinforce existing disease-specific metrics or begin to move us toward a more 
holistic, multi-morbidity framework. 
15 Future Research 
     Although we are accumulating evidence of obvious overtreatment (near normal 
HbA1c targets for older adults with limited life expectancy), we do not know the effects 
of varying levels of intermediate control on longer-term outcomes in this more complex 
patient population. The ACCORD, ADVANCE, and VADT illuminated potential 
immediate or concurrent harms associated with attempting to achieve near-normal blood 
glucose control (HbA1c of <6.5%) in older patients with cardiac complications,4, 52 but 
there are no randomized controlled trials exploring the long-term effects of managing 
more complex patients to the less stringent HbA1c targets mentioned in the existing 
guidelines (7.5%-9%). 
     While we await trials comparing HbA1c treatment targets between 7% and 8% to 
targets between 8% and 9% for older adults on patient-centered outcomes, the next best 
available study design is the prospective or retrospective cohort. Although cohort studies 
suffer from selective attrition and latent variable bias (unmeasured confounding), they 
can be particularly useful in investigating potential linkages between intermediate 
outcomes often studied in randomized controlled trials (e.g. HbA1c control or 
albuminuria) and rate of downstream complications patients care about (e.g. death, end-
stage renal disease). These links are generally assumed, but not empirically supported.60 
     Future work, to be completed during the primary investigator’s (EM’s) post-doctoral 
appointment, will use medical claims data and electronic health record information to 
assign diabetic cases to one of three clinical complexity levels at baseline (based on the 
ADA/AGS guidelines): relatively heathy, complex/intermediate, and very complex/poor.7 
Then, we will consider the effects of varying levels of HbA1c control by complexity 
status at baseline on future, patient-centered outcomes including: hyper- and 
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hypoglycemic hospitalizations, cardiovascular events, and death (all-cause, 
cardiovascular, ESRD). This study will advance the literature by considering the effects 
of varying levels of glycemic control at varying levels of patient complexity over time. 
The results of this study will help us better define individualized care for patients who 
have already accumulated many of the microvascular and macrovascular complications 
of diabetes, for the purpose of  maximizing their remaining quality of life.  
     Recent discussions of more aggressive blood pressure control, prompted by the 
Systolic Blood Pressure Intervention (SPRINT) Trial, may offer additional opportunities 
to analyze patient outcomes associated with various levels of control in complex, older 
adult populations.192 Unlike the equivocal research surrounding glycemic control, treating 
hypertension and high cholesterol reduces the risk of macrovascular events (even in 
patients over 80 years old).192, 193 A meta-analysis of 90,056 patients from 14 randomized 
controlled trials (RCTs) showed that diabetics 65 years and older (n=6446) treated with 
statin therapy to reduce high cholesterol had an 18% reduction in the risk of major 
cardiovascular events, similar to the 22% reduction in risk in younger populations. Statins 
are effective treatment independent of patient’s age.193 The Systolic Blood Pressure 
Intervention Trial (SPRINT) recently showed a reduction of fatal and nonfatal 
cardiovascular events with tight blood pressure control, even in those over 75 years of 
age, without a significant increase in harms.192 Blood pressure and cholesterol control can 
also help slow the development of microvascular complications,37, 42 but are not the focus 
of this particular study. Future work will consider the effects of varying levels of blood 
pressure and cholesterol control on downstream morbidity and mortality by patient age 
and clinical complexity. 
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17 Figures & Tables 
 
Figure 1. Conceptual Models 
Model 1. Effect of Patient (Vignette) and Provider Factors on a Clinicians’ Decision to 
Intensify Medication Therapy and Subsequent Choice of Second-Line Medication (if 
Intensify) 
 
 
 
Model 2. Partially Mediating Effect of Clinician Predicted Adherence on the Decision to 
Intensify Medication Therapy 
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Figure 2. ADA 2016 General Recommendations for Glycemic Targets 
 A reasonable A1C goal for many nonpregnant adults is 7% (53 
mmol/mol). 
 Providers might reasonably suggest more stringent A1C goals (such as 
6.5% [48 mmol/mol]) for selected individual patients if this can be 
achieved without significant hypoglycemia or other adverse effects of 
treatment. Appropriate patients might include those with short duration of 
diabetes, type 2 diabetes treated with lifestyle or metformin only, long life 
expectancy, or no significant cardiovascular disease.  
 Less stringent A1C goals (such as 8% [64 mmol/mol]) may be appropriate 
for patients with a history of severe hypoglycemia, limited life expectancy, 
advanced microvascular or macrovascular complications, extensive 
comorbid conditions, or long-standing diabetes in whom the general goal 
is difficult to attain despite diabetes self-management education, 
appropriate glucose monitoring, and effective doses of multiple glucose-
lowering agents including insulin.  
 
Adapted from ADA 2016 Recommendations, Chapter 5. Glycemic Targets, p. S4165 
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Figure 1.1. Sample Vignette 
Mrs. Brown is 80 years old and has had type 2 diabetes for 15 years. Three months ago, Mrs. Brown 
was prescribed Metformin 1000 mg (BID), an ACE inhibitor to control comorbid hypertension, and a low-
dose aspirin. Mrs. Brown currently has a HbA1c of 7.5%, a BP of 140/80 mmHg, and a BMI of 29. Her 
basic metabolic profile is normal and GFR > 60. Mrs. Brown has coronary artery disease, for which she 
underwent a coronary artery bypass graft five years ago. Mrs. Brown reports an intermittent pain in her 
feet, but has difficulty localizing it. There is no history of depression. Mrs. Brown has some recent 
memory loss on formal testing. She lives independently, but depends on her eldest daughter to keep 
her medical appointments and pay her bills. She stopped driving, in part because she occasionally got 
lost. Mrs. Brown is able to afford her medications.  
 
1. Which anti-hyperglycemic treatment option are you most likely to recommend? Mark only one. 
 
☐     Continue Metformin (Glucophage) Monotherapy 
☐     Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
☐     Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
☐     Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
☐     Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
☐     Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, Levemir) 
 
2. How likely is the patient to adhere to your medication recommendations? Mark only one. 
 
☐     Very likely to adhere  
☐     Somewhat likely to adhere  
☐     Somewhat unlikely to adhere  
☐     Very unlikely to adhere  
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Figure 1.2. Treatment Intensification for the Most and Least Complex Patient by Clinician 
Type 
80-Year-Old, Cognitive Impairment, Heart Disease 
 
65-Year-Old, No Cognitive Impairment, No Heart Disease
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Figure 2.1 Sample Vignette 
Mrs. Brown is 80 years old and has had type 2 diabetes for 15 years. Three months ago, Mrs. Brown 
was prescribed Metformin 1000 mg (BID), an ACE inhibitor to control comorbid hypertension, and a low-
dose aspirin. Mrs. Brown currently has a HbA1c of 7.5%, a BP of 140/80 mmHg, and a BMI of 29. Her 
basic metabolic profile is normal and GFR > 60. Mrs. Brown has coronary artery disease, for which she 
underwent a coronary artery bypass graft five years ago. Mrs. Brown reports an intermittent pain in her 
feet, but has difficulty localizing it. There is no history of depression. Mrs. Brown has some recent 
memory loss on formal testing. She lives independently, but depends on her eldest daughter to keep 
her medical appointments and pay her bills. She stopped driving, in part because she occasionally got 
lost. Mrs. Brown is able to afford her medications.  
 
3. Which anti-hyperglycemic treatment option are you most likely to recommend? Mark only one. 
 
☐     Continue Metformin (Glucophage) Monotherapy 
☐     Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
☐     Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
☐     Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
☐     Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
☐     Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, Levemir) 
 
4. How likely is the patient to adhere to your medication recommendations? Mark only one. 
 
☐     Very likely to adhere  
☐     Somewhat likely to adhere  
☐     Somewhat unlikely to adhere  
☐     Very unlikely to adhere  
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Figure 2.2. Probability of Choosing Insulin or Sulfonylureas by Complexity and HbA1c 
Level 
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Figure 3.1. Partial Mediation Model Explored in the Current Vignette Study 
A. Does patient cognitive impairment affect clinician adherence predictions? 
 
 
B. Does patient cognitive impairment affect clinician antiglycemic treatment targets? 
 
 
 
 
C. Do clinician adherence predictions partially explain, or mediate the relationship between 
patient cognitive impairment and antiglycemic treatment targets?  
 
 
 
 
 
 
Patient Cognitive Impairment Clinician Adherence Prediction 
Patient Cognitive Impairment Clinician Decision to Intensify 
Anti-glycemic Medications to 
Achieve Tighter Control 
 
Patient Cognitive Impairment Clinician Decision to Intensify 
Antiglycemic Medications to 
Achieve Tighter Control 
 
Clinician Adherence Prediction 
a 
a b 
c 
c' 
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Figure 3.2. Sample Vignette 
Mrs. Brown is 80 years old and has had type 2 diabetes for 15 years. Three months ago, Mrs. 
Brown was prescribed Metformin 1000 mg (BID), an ACE inhibitor to control comorbid 
hypertension, and a low-dose aspirin. Mrs. Brown currently has a HbA1c of 7.5%, a BP of 
140/80 mmHg, and a BMI of 29. Her basic metabolic profile is normal and GFR > 60. Mrs. 
Brown has coronary artery disease, for which she underwent a coronary artery bypass 
graft five years ago. Mrs. Brown reports an intermittent pain in her feet, but has difficulty 
localizing it. There is no history of depression. Mrs. Brown has some recent memory loss on 
formal testing. She lives independently, but depends on her eldest daughter to keep her 
medical appointments and pay her bills. She stopped driving, in part because she 
occasionally got lost. Mrs. Brown is able to afford her medications.  
 
5. Which anti-hyperglycemic treatment option are you most likely to recommend? Mark 
only one. 
 
☐     Continue Metformin (Glucophage) Monotherapy 
☐     Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
☐     Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
☐     Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
☐     Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
☐     Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, 
Levemir) 
 
6. How likely is the patient to adhere to your medication recommendations? Mark only 
one. 
 
☐     Very likely to adhere  
☐     Somewhat likely to adhere  
☐     Somewhat unlikely to adhere  
☐     Very unlikely to adhere  
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Figure 3.3. Predicted Adherence Affects Targets More for Older, More Complex Patients 
A. Clinician adherence predictions less important in decision to intensify antihyperglycemic therapy for 
younger, otherwise healthy people with type 2 diabetes and evidence of cognitive impairment 
 
 
 
 
 
 
 
 
B. Clinician adherence predictions more important in decision to intensify antihyperglycemic therapy for 
older, sicker people with type 2 diabetes and evidence of cognitive impairment 
 
 
 
 
 
 
 
 
 
65 year-old, newly diagnosed 
diabetes, no heart disease, and 
cognitive impairment 
Clinician Decision to Intensify 
Antiglycemic Medications to 
Achieve Tighter Control 
 
Clinician Adherence Prediction 
80 year-old, longstanding diabetes, 
advanced heart disease, and cognitive 
impairment 
Clinician Decision to Intensify 
Antiglycemic Medications to 
Achieve Tighter Control 
Clinician Adherence Prediction 
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Table 1. Outcomes of Three Large Trials Comparing Intensive Glycemic Control to 
Standard Control among Patients with Established Type 2 Diabetes and 
Complications 
  
ACCORD 
(1999-2008) 
ADVANCE 
(2001-2008 
VADT 
(2000-2008) 
Mean HbA1c -  
Intensive Control 
(I) 
6.4% 6.50% 6.90% 
Mean HbA1c -  
Standard Control 
(S) 
7.5% 7.30% 8.40% 
Mean Age ± SD 62±7 66±6 60±9 
≥80 Years Old (%) 0.5 1.6 NR 
All-Cause  
Mortality I>S NS NS 
Cardiovascular 
Mortality I>S NS NS 
Macrovascular 
Complications I>S NS NS 
Microvascular 
Complications 
Albuminuria I<S 
Nephropathy/Retino
pathy: NS 
Major Microvascular 
Event (driven by 
nephropathy):I<S 
Albuminuria I<S, 
Nephropathy/Neuropath
y/Retinopathy:NS 
Hypoglycemic   
Events 
I>S I>S I>S 
NR = Not Reported 
NS = Not Significant 
I>S = Outcome significantly higher in intensive treatment arm compared to standard treatment 
I<S = Outcome significantly lower in intensive treatment arm compared to standard treatment 
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Table 2. ADA (2016) Guidelines for Older Adults with AGS (2013) Thresholds for 
Comparison 
Patient Characteristics / Health 
Status 
Rationale Reasonable 
A1C goal‡ 
AGS (2013) 
Healthy 
(few coexisting chronic illnesses, 
intact cognitive and functional status) 
Longer remaining life 
expectancy 
<7.5% 
(58 mmol/mol) 
7%-7.5% 
Complex/intermediate  
(multiple coexisting chronic illnesses* 
or 2+ instrumental ADL impairments 
or mild-to-moderate cognitive 
impairment) 
Intermediate remaining life 
expectancy, high treatment 
burden, hypoglycemia 
vulnerability, fall risk 
<8.0% 
(64 mmol/mol) 
7.5%-8% 
Very complex/poor health 
(LTC or end-stage chronic illnesses** 
or moderate-to-severe cognitive 
impairment or 2+ ADL dependencies) 
Limited remaining life 
expectancy makes benefit 
uncertain 
<8.5%† 
(69 mmol/mol) 
8%-9% 
‡A lower A1C goal may be set for an individual if achievable without recurrent or severe 
hypoglycemia or undue treatment burden. 
*Coexisting chronic illnesses are conditions serious enough to require medications or lifestyle 
management and may include arthritis, cancer, congestive heart failure, depression, emphysema, falls, 
hypertension, incontinence, stage 3 or worse chronic kidney disease, myocardial infarction, and stroke. 
By “multiple,” we mean at least three, but many patients may have five or more. 
**The presence of a single end-stage chronic illness, such as stage 3–4 congestive heart failure or 
oxygen-dependent lung disease, chronic kidney disease requiring dialysis, or uncontrolled metastatic 
cancer, may cause significant symptoms or impairment of functional status and significantly reduce 
life expectancy. 
†A1C of 8.5% (69 mmol/mol) equates to an estimated average glucose of 200 mg/dL (11.1 mmol/L). 
Looser A1C targets above 8.5% (69 mmol/mol) are not recommended as they may expose patients to 
more frequent higher glucose values and the acute risks from glycosuria, dehydration, hyperglycemic 
hyperosmolar syndrome, and poor wound healing 
Adapted from ADA (2016), Chapter 10., Table 10.1 (adapted), p.S83  
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Table 3. Dual Therapy Comparisons 
  Metformin + 
Sulfonylurea 
Metformin + 
Thiazolidinedione  
Metformin + 
DPP-4 
Metformin + 
GLP-1 
Metformin + 
Insulin 
Efficacy High High Intermediate High High 
Hypoglycemic 
Risk 
Moderate Risk Low Risk Low Risk Low Risk Highest Risk 
Weight Gain Gain Neutral Loss Gain 
Side Effects Hypoglycemia Edema, HF Rare GI Hypoglycemic 
Costs Low Low High High Variable 
*ADA (2016) Approaches to Glycemic Management, Figure 7.1, adapted 
 
Table 4. Vignette Factors and Levels 
Vignette Factor Level 1 Level 2 
Glycated Hemoglobin 
(HbA1c) 
HbA1c of 7.5% HbA1c of 8.5% 
Age/Disease Duration 65 years old / type 2 diabetes 
for 5 years 
80 years old / type 2 diabetes 
for 15 years 
Presence of Cognitive 
Impairment 
[no information] Some recent memory loss on 
formal testing 
She lives independently, but 
depends on her eldest daughter 
to keep her medical 
appointments and pay her bills 
She stopped driving, in part 
because she occasionally got 
lost 
History of Heart Disease no history of cardiovascular 
disease 
coronary artery disease, for 
which she underwent a 
coronary artery bypass graft 
five years ago. 
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Table 1.1. ADA (2016) Guidelines for Older Adults with AGS (2013) Thresholds for 
Comparison 
 
Patient Characteristics / Health 
Status 
Rationale Reasonable 
A1C goal‡ 
AGS (2013) 
Healthy 
(few coexisting chronic illnesses, 
intact cognitive and functional status) 
Longer remaining life 
expectancy 
<7.5% 
(58 mmol/mol) 
7%-7.5% 
Complex/intermediate  
(multiple coexisting chronic illnesses* 
or 2+ instrumental ADL impairments 
or mild-to-moderate cognitive 
impairment) 
Intermediate remaining life 
expectancy, high treatment 
burden, hypoglycemia 
vulnerability, fall risk 
<8.0% 
(64 mmol/mol) 
7.5%-8% 
Very complex/poor health 
(LTC or end-stage chronic illnesses** 
or moderate-to-severe cognitive 
impairment or 2+ ADL dependencies) 
Limited remaining life 
expectancy makes benefit 
uncertain 
<8.5%† 
(69 mmol/mol) 
8%-9% 
‡A lower A1C goal may be set for an individual if achievable without recurrent or severe 
hypoglycemia or undue treatment burden. 
*Coexisting chronic illnesses are conditions serious enough to require medications or lifestyle 
management and may include arthritis, cancer, congestive heart failure, depression, emphysema, falls, 
hypertension, incontinence, stage 3 or worse chronic kidney disease, myocardial infarction, and stroke. 
By “multiple,” we mean at least three, but many patients may have five or more. 
**The presence of a single end-stage chronic illness, such as stage 3–4 congestive heart failure or 
oxygen-dependent lung disease, chronic kidney disease requiring dialysis, or uncontrolled metastatic 
cancer, may cause significant symptoms or impairment of functional status and significantly reduce 
life expectancy. 
†A1C of 8.5% (69 mmol/mol) equates to an estimated average glucose of 200 mg/dL (11.1 mmol/L). 
Looser A1C targets above 8.5% (69 mmol/mol) are not recommended as they may expose patients to 
more frequent higher glucose values and the acute risks from glycosuria, dehydration, hyperglycemic 
hyperosmolar syndrome, and poor wound healing 
Adapted from ADA (2016), Chapter 10., Table 10.1 (adapted), p.S83  
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Table 1.2. Vignette Factors and Levels 
Vignette Factor Level 1 Level 2 
Glycated Hemoglobin 
(HbA1c) 
HbA1c of 7.5% HbA1c of 8.5% 
Age/Disease Duration 65 years old / type 2 diabetes 
for 5 years 
80 years old / type 2 diabetes 
for 15 years 
Presence of Cognitive 
Impairment 
[no information] Some recent memory loss on 
formal testing 
She lives independently, but 
depends on her eldest daughter 
to keep her medical 
appointments and pay her bills 
She stopped driving, in part 
because she occasionally got 
lost 
History of Heart Disease no history of cardiovascular 
disease 
coronary artery disease, for 
which she underwent a 
coronary artery bypass graft 
five years ago. 
 
Table 1.3. Respondent Characteristics 
  
Total Sample 
(N=336) 
Family Practice 
(N=108) 
Internal 
Medicine  
(N=73) 
Nurse 
Practitioners 
(N=155) 
  
Mean 
(Range) 
Mean 
(Range) 
Mean 
(Range) 
Mean 
(Range) 
Year Completed 
Professional 
Education  
1996 
(1955-2015) 
1991 
(1968-2015) 
1986 
(1955-2011) 
2003 
(1978-2015) 
Length of Routine 
Visit (Minutes) 
23 
(5-90) 
21 
(7-45) 
22 
(5-90) 
24 
(5-60) 
Medicare Patients as a Percent of Total Practice 
< 25% 28% 39% 16% 25% 
25% - 75% 52% 50% 64% 48% 
> 75% 20% 11% 19% 26% 
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Table 1.4. Rate of Anti-Hyperglycemic Treatment Intensification by Vignette 
Characteristics 
  
All Vignettes 
(n=1,344) 
HbA1c=7.5% 
(n=652) 
HbA1c=8.5% 
(n=692) 
  
Percent 
Intensified 
(%) 
Pearson 
χ2 
Percent 
Intensified 
(%) 
Pearson 
χ2 
Percent 
Intensified  
(%) 
Pearson 
χ2 
HbA1c             
7.50% 55.67 145.7 
** 
        
8.50% 85.55         
Age             
65-Year-Old 81.39 
74.2** 
70.43 
64.7** 
92.24 
25.4** 
80-Year-Old 60.06 39.09 78.78 
Heart Disease             
No Heart Disease 68.37 
4.6* 
53.99 
0.80 
82.25 
5.8* 
Heart Disease 73.68 57.36 88.70 
Cognitive Impairment             
No Cognitive Impairment 77.16 
25.2** 
60.56 
6.1* 
91.97 
25.1** 
Cognitive Impairment 64.75 50.91 78.55 
*p<.05, **p<.01 
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Table 1.5. Effect of Patient and Clinician Characteristics on Intensification  
  
Model 1.  
Patient 
Characteristics 
Model 2.  
Patient & 
Clinician 
Characteristics 
Model 3. 
Patient-Level  
Interactions 
Model 4. 
Clinician-Level
Interactions 
  
Percentage 
Points 
(SE) 
Percentage 
Points 
(SE) 
Percentage 
Points 
(SE) 
Percentage 
Points 
(SE) 
Patient Characteristics 
8.5% HbA1c 
31.7** 
(.02) 
31.7** 
(.02) 
31.5** 
(.04) 
31.1** 
(.03) 
80-Year-Old 
-20.8** 
(.02) 
-20.9** 
(.02) 
-23.2** 
(.03) 
-20.8** 
(.02) 
Heart Disease 
3.0 
(.02) 
3.0 
(.02) 
-0.0 
(.02) 
3.5 
(.02) 
Cognitive Impairment 
-10.6** 
(.02) 
-10.6 
(.02) 
-5.9* 
(.02) 
-8.6** 
(.02) 
Clinician Characteristics 
Clinician Type (ref. Nurse Practitioner)       
General Internist 
-2.2 
(.04) 
-3.9 
(.04) 
-3.8 
(.04) 
Family Practice 
-14.6** 
(.04) 
-16.3** 
(.04) 
-13.1 
(.05) 
Length of Routine Visit > 20 Minutes 
-.8 
(.03)     
>75% of Practice is Medicare Patients  
-1.0 
(.04)     
Completed Education in Last 5 Years 
6.0 
(.03)     
HbA1c Interactions with Patient Factors     
HbA1c 8.5%*80-Year-Old 
4.9 
(.04)   
HbA1c 8.5%*Heart Disease 
7.2 
(.04)   
HbA1c 8.5%*Cognitive Impairment 
-11.7** 
(.04)   
Family Medicine Interactions   
Family Medicine*HbA1c 8.5%  
1.5 
(.04) 
Family Medicine*80-Year-Old 
1.5 
(.04) 
Family Medicine*Heart Disease 
-.9 
(.04) 
Family Medicine*Cognitive Impairment 
-5.4 
(.04) 
Model Intraclass 
Correlation 0.63 0.60 0.63 0.61 
*p<.05, **p<.01 
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Table 2.1. Dual Therapy Comparisons 
  Metformin + 
Sulfonylurea 
Metformin + 
Thiazolidinedione  
Metformin + 
DPP-4 
Metformin + 
GLP-1 
Metformin + 
Insulin 
Efficacy High High Intermediate High High 
Hypoglycemic 
Risk 
Moderate Risk Low Risk Low Risk Low Risk Highest Risk 
Weight Gain Gain Neutral Loss Gain 
Side Effects Hypoglycemia Edema, HF Rare GI Hypoglycemic 
Costs Low Low High High Variable 
*ADA (2016) Approaches to Glycemic Management, Figure 7.1, adapted 
 
Table 2.2. Vignette Factors and Levels 
Vignette Factor Level 1 Level 2 
Glycated Hemoglobin 
(HbA1c) 
HbA1c of 7.5% HbA1c of 8.5% 
Age/Disease Duration 65 years old / type 2 diabetes 
for 5 years 
80 years old / type 2 diabetes 
for 15 years 
Presence of Cognitive 
Impairment 
[no information] Some recent memory loss on 
formal testing 
She lives independently, but 
depends on her eldest daughter 
to keep her medical 
appointments and pay her bills 
She stopped driving, in part 
because she occasionally got 
lost 
History of Heart Disease no history of cardiovascular 
disease 
coronary artery disease, for 
which she underwent a 
coronary artery bypass graft 
five years ago. 
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Table 2.3. Respondent Characteristics 
  
Total Sample 
(N=336) 
Family Practice 
(N=108) 
Internal 
Medicine  
(N=73) 
Nurse 
Practitioners 
(N=155) 
  
Mean 
(Range) 
Mean 
(Range) 
Mean 
(Range) 
Mean 
(Range) 
Year Completed 
Professional 
Education  
1996 
(1955-2015) 
1991 
(1968-2015) 
1986 
(1955-2011) 
2003 
(1978-2015) 
Length of Routine 
Visit (Minutes) 
23 
(5-90) 
21 
(7-45) 
22 
(5-90) 
24 
(5-60) 
Medicare Patients as a Percent of Total Practice 
< 25% 28% 39% 16% 25% 
25% - 75% 52% 50% 64% 48% 
> 75% 20% 11% 19% 26% 
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Table 2.4. Bivariate Relationship between Vignette Factors and Second-Line 
Medication Choice  
  
Sulfonylurea
(34%) 
Insulin
(13%) 
TZD 
(7%) 
GLP-1
(10%) 
DPP-4 
(35%)   
  % % % % % χ2 
HbA1c             
7.5% 34.7 7.7 8.0 9.6 39.9 17.3** 
8.5% 33.9 16.3 6.4 10.9 32.5 
              
Age             
65-Year-Old 35.6 13.5 6.2 11.5 33.2 6.0 
80-Year-Old 32.1 12.3 8.2 8.7 38.6 
              
Heart Disease             
No Heart Disease 33.9 11.0 8.4 9.9 36.8 5.6 
Heart Disease 34.5 14.8 5.8 10.8 34.1 
              
Cognitive Impairment*             
No Cognitive Impairment 34.6 16.5 5.5 12.4 31.0 25.9** 
Cognitive Impairment 33.7 8.7 8.9 8.0 40.8 
*p<.05, **p<.01 
TZD = Thiazolidinedione, GLP-1 = GLP-1 Receptor Agonist, DPP-4 = DPP-4 Inhibitor 
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Table 2.5. Effect of Vignette and Clinician Factors on Second-Line Anti-
Hyperglycemic Medication Choice 
  Sulfonylurea Insulin TZD GLP DPP4 
  
Percentage 
Points 
(SE) 
Percentage
Points 
(SE) 
Percentage
Points 
(SE) 
Percentage 
Points 
(SE) 
Percentage
Points 
(SE) 
Patient Characteristics           
8.5% HbA1c 1.2 
(.03) 
6.3* 
(.03) 
-0.8 
(.02) 
0.5 
(.02) 
-7.2* 
(.03) 
80-Year-Old -3.9 
(.03) 
-1.6 
(.03) 
0.7 
(.02) 
-3.8 
(.02) 
8.6* 
(.01) 
Heart Disease 0.4 
(.03) 
2.4 
(.02) 
-2.6 
(.02) 
1.0 
(.02) 
-1.3 
(.03) 
Cognitive Impairment 0.5 
(.03) 
-7.3** 
(.02) 
3.5* 
(.01) 
-4.5* 
(.02) 
7.8* 
(.03) 
Clinician 
Characteristics           
Clinician Type  
(ref. Nurse Practitioner)           
Internal Medicine 16.3* 
(.07) 
-3.2 
(.05) 
-2.5 
(.03) 
-4.4 
(.05) 
-6.2 
(.07) 
Family Practice 11.0 
(.06) 
-4.4 
(.04) 
0.5 
(.03) 
-1.7 
(.04) 
-5.4 
(.06) 
Length of Routine Visit 
> 20 Minutes 
-4.9 
(.05) 
.2 
(.03) 
-.6 
(.03) 
.5 
(.03) 
4.8 
(.05) 
>75% of Practice is 
Medicare Patients  
-.1.8 
(.05) 
12.2* 
(.04) 
-2.7 
(.02) 
-3.2 
(.03) 
-4.6 
(.05) 
Completed Education in 
Last 5 Years 
7.4 
(.05) 
-4.5 
(.03) 
3.0 
(.03) 
3.5 
(.03) 
-9.5 
(.05) 
*p<.05 
TZD = Thiazolidinedione, GLP-1 = GLP-1 Receptor Agonist, DPP-4 = DPP-4 Inhibitor 
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Table 3.1. Vignette Factors and Levels 
Vignette Factor Level 1 Level 2 
Glycated Hemoglobin 
(HbA1c) 
HbA1c of 7.5% HbA1c of 8.5% 
Age/Disease Duration 65 years old / type 2 diabetes 
for 5 years 
80 years old / type 2 diabetes 
for 15 years 
Presence of Cognitive 
Impairment 
[no information] Some recent memory loss on 
formal testing 
She lives independently, but 
depends on her eldest daughter 
to keep her medical 
appointments and pay her bills 
She stopped driving, in part 
because she occasionally got 
lost 
History of Heart Disease no history of cardiovascular 
disease 
coronary artery disease, for 
which she underwent a 
coronary artery bypass graft 
five years ago. 
 
 
Table 3.2. Respondent Characteristics 
  
Total Sample 
(N=336) 
Family Practice 
(N=108) 
Internal 
Medicine  
(N=73) 
Nurse 
Practitioners 
(N=155) 
  
Mean 
(Range) 
Mean 
(Range) 
Mean 
(Range) 
Mean 
(Range) 
Year Completed 
Professional 
Education  
1996 
(1955-2015) 
1991 
(1968-2015) 
1986 
(1955-2011) 
2003 
(1978-2015) 
Length of Routine 
Visit (Minutes) 
23 
(5-90) 
21 
(7-45) 
22 
(5-90) 
24 
(5-60) 
Medicare Patients as a Percent of Total Practice 
< 25% 28% 39% 16% 25% 
25% - 75% 52% 50% 64% 48% 
> 75% 20% 11% 19% 26% 
 
 
 
 97 
 
 
Table 3.3. Relationship between Patient Vignette Characteristics and Clinician 
Predicted Adherence 
  
Age 
Cognitive  
Impairment 
(CI) 
Heart Disease
(HD) 
Glycated 
Hemoglobin  
(HbA1c) 
  65 80 No CI CI 
No 
HD HD 7.5% 8.5% 
Unlikely to 
Adhere 11.4% 12.4% 3.1% 21.0% 12.1% 11.8% 11.7% 12.1% 
Likely To 
Adhere 88.6% 87.6% 96.9% 79.0% 88.0% 88.2% 88.3% 87.90%
Pearson χ2 0.35 103.3** 0.03 0.07 
*p<.05, **p<.01 
 
 
Table 3.4. Relationship between Patient Vignette Characteristics and a Clinician’s 
Decision to Intensify Medication Therapy 
  
Age 
Cognitive  
Impairment 
(CI) 
Heart Disease
(HD) 
Glycated 
Haemoglobin 
(HbA1c) 
  65 80 No CI CI 
No 
HD HD 7.5% 8.5% 
No Intensify 18.6% 39.9% 22.8% 35.3% 31.6% 26.3% 44.3% 14.5% 
Intensify 81.4% 60.1% 77.2% 64.8% 68.4% 73.7% 55.7% 85.60%
Pearson χ2 74.2** 25.2** 4.6* 145.7** 
*p<.05, **p<.01 
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Table 3.5. Mediation Relationships from Mixed Effects Probit Regressions 
Relationship being 
Tested X→Y X→M 
M→Y  
(when X present) 
Key Finding 
1. Cognitive 
Impairment Negatively 
Related to Treatment 
Intensification 
2. Cognitive 
Impairment 
Negatively Related to 
Predicted Adherence 
3. Predicted adherence 
not significantly related 
to treatment 
intensification 
  
Percentage 
Points 
(SE) 
Percentage 
Points 
(SE) 
Percentage 
Points 
(SE) 
Patient 
Characteristics       
Cognitive 
Impairment 
-10.6** 
(.02) 
-18.7** 
(.02) 
-10.0** 
(.02) 
8.5% HbA1c 
31.7** 
(.02) 
-1.5 
(.01) 
31.8** 
(.02) 
80-Year-Old 
20.9** 
(.02) 
-.9 
(.01) 
-20.9** 
(.02) 
Heart Disease 
3.0 
(.02) 
0.1 
(.01) 
3.0 
(.02) 
Provider 
Characteristics       
Practitioner Type 
(ref. Nurse 
Practitioner)       
General Internist 
-2.2 
(.04) 
-5.2 
(.03) 
-2.0 
(.04) 
Family Practice 
-14.5** 
(.04) 
-1.7 
(.03) 
-14.5** 
(.04) 
Length of Routine 
Visit > 20 Minutes 
-.8 
(.03) 
-5.5* 
(.02) 
-.6 
(.03) 
>75% of Practice is 
Medicare Patients  
-1.0 
(.04) 
3.9 
(.03) 
-1.2 
(.04) 
Completed 
Education in Last 5 
Years 
6.0 
(.03) 
.9 
(.03) 
6.1 
(.03) 
Clincian Predicts 
Patient will be 
Adherent     
3.0 
(.03) 
*p<.05, **p<.01 
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Table 5. Summary of Findings for Papers 1 and 2. 
Factor Comparator 
Medication 
Intensification 
Choose Sulfonylurea 
or Insulin 
HbA1c of 8.5% 7.5% + 32% + 8% 
80, Long Disease 
Duration 
65, Short Disease 
Duration - 21% - 6% 
Cognitive Impairment No information - 11% - 10% 
Heart Disease 
requiring CABG 
No history of heart 
disease NS NS 
Family Medicine Nurse Practitioner - 16% NS 
Over 75% of practice 
Medicare ≤75% Medicare NS + 11% 
Most Complex, 
HbA1c 7.5% 
(predicted 
probability) NA 35% 36% 
Least Complex, 
HbA1c 7.5% 
(predicted 
probability) NA 75% 50% 
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18 Appendices 
 
Appendix A. Sample Consent Form and Survey 
 
CONSENT STATEMENT 
Diabetic Anti-Hyperglycemic Medication Survey 
 
You are invited to complete a survey on diabetic anti-hyperglycemic medications. Please read this form and 
ask any questions you may have before agreeing to complete the survey. This study is being conducted as 
part of a dissertation requirement for the University of Minnesota, Health Services Research, Policy and 
Administration Program.  
 
Background Information 
 
This project seeks to understand how primary care physicians choose between available anti-hyperglycemic 
medications and predict adherence. The results of this survey will provide information to researchers and 
educators.  
 
Procedures 
 
If you agree to participate, you will be asked to complete a short survey in which you will be given four 
short clinical scenarios and asked to recommend a course of treatment. The survey should take about 4 
minutes. 
 
Risks and Benefits of Being in the Study 
 
There are no immediate or expected risks for participating in the survey. You are simply helping us 
understand how physicians treat diabetic patients. The survey is completely anonymous.  
 
There are also no immediate or expected benefits to you for participating in the survey.   
 
Voluntary Nature of the Study 
 
If you decide to participate, you are free to withdraw at any time.  
 
Contacts and Questions 
 
The researcher conducting this study is Ellen McCreedy. You may ask any questions you have now. If you 
have questions later, you may contact her at 813-731-4241. If you have any questions or concerns 
regarding the study and would like to talk to someone other than the researcher, contact Research Subjects’ 
Advocate line, D528 Mayo, 420 Delaware Street S.E., Minneapolis, Minnesota 55455; telephone (612) 
625-1650. 
 
 
 
You may have a copy of this form to keep for your records. 
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Diabetic Anti-Hyperglycemic Medication 
Survey
 
Thank you for helping with this survey. We appreciate you sharing your time and 
expertise. Please note that your responses are anonymous. This survey takes 
approximately 4 minutes to complete. Feel free to add any additional comments at the 
end of the survey. 
 
 
Part I. Patient Vignettes 
Instructions: For each of the following hypothetical type 2 diabetics, please determine the 
appropriate anti-hyperglycemic medication treatment option and the extent to which the patient is 
likely to be adherent to this treatment. Please try to make a decision with the information 
provided in the vignettes. 
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Vignette 1. Mrs. Williams is 65 years old and has had type 2 diabetes for 5 years. 
Three months ago, Mrs. Williams was prescribed Metformin 1000 mg (BID), an ACE 
inhibitor to control comorbid hypertension, and a low-dose aspirin. Mrs. Williams 
currently has a HbA1c of 8.5%, a BP of 140/80 mmHg, and a BMI of 29. Her basic 
metabolic profile is normal and GFR > 60. Mrs. Williams has coronary artery disease, 
for which she underwent a coronary artery bypass graft five years ago. Mrs. 
Williams reports an intermittent pain in her feet, but has difficulty localizing it. There is 
no history depression. Mrs. Williams is able to afford her medications. 
 
 
1. Which anti-hyperglycemic treatment option are you most likely to recommend? Mark 
only one. 
 
☐     Continue Metformin (Glucophage) Monotherapy, Same Dose  
☐     Continue Metformin (Glucophage) Monotherapy, Increase Dose 
☐     Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
☐     Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
☐     Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
☐     Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
☐     Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, 
Levemir) 
 
2. How likely is the patient to adhere to your medication recommendations? Mark only one. 
 
☐     Very likely to adhere  
☐     Somewhat likely to adhere  
☐     Somewhat unlikely to adhere  
☐     Very unlikely to adhere 
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Vignette 2. Mrs. Johnson is 80 years old and has had type 2 diabetes for 15 years. 
Three months ago, Mrs. Johnson was prescribed Metformin 1000 mg (BID), an ACE 
inhibitor to control comorbid hypertension, and a low-dose aspirin. Mrs. Johnson 
currently has a HbA1c of 7.5%, a BP of 140/80 mmHg, and a BMI of 29. Her basic 
metabolic profile is normal and GFR > 60. Mrs. Johnson reports an intermittent pain in 
her feet, but has difficulty localizing it. There is no history of cardiovascular disease or 
depression. Mrs. Johnson is able to afford her medications. 
 
1. Which anti-hyperglycemic treatment option are you most likely to recommend? Mark 
only one. 
 
☐     Continue Metformin (Glucophage) Monotherapy, Same Dose  
☐     Continue Metformin (Glucophage) Monotherapy, Increase Dose 
☐     Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
☐     Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
☐     Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
☐     Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
☐     Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, 
Levemir) 
 
2. How likely is the patient to adhere to your medication recommendations? Mark only one. 
 
☐     Very likely to adhere  
☐     Somewhat likely to adhere  
☐     Somewhat unlikely to adhere  
☐     Very unlikely to adhere 
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Vignette 3. Mrs. Jones is 65 years old and has had type 2 diabetes for 5 years. Three 
months ago, Mrs. Jones was prescribed Metformin 850 mg (BID), an ACE inhibitor to 
control comorbid hypertension, and a low-dose aspirin. Mrs. Jones currently has a 
HbA1c of 7.5%, a BP of 140/80 mmHg, and a BMI of 29. Her basic metabolic profile is 
normal and GFR > 60. Mrs. Jones reports an intermittent pain in her feet, but has 
difficulty localizing it. There is no history of cardiovascular disease or depression. Mrs. 
Jones has some recent memory loss on formal testing. She lives independently, but 
depends on her eldest daughter to keep her medical appointments and pay her bills. 
She stopped driving, in part because she occasionally got lost. Mrs. Jones is able to 
afford her medications.  
 
1. Which anti-hyperglycemic treatment option are you most likely to recommend? Mark 
only one. 
 
☐     Continue Metformin (Glucophage) Monotherapy, Same Dose  
☐     Continue Metformin (Glucophage) Monotherapy, Increase Dose 
☐     Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
☐     Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
☐     Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
☐     Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
☐     Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, 
Levemir) 
 
2. How likely is the patient to adhere to your medication recommendations? Mark only one. 
 
☐     Very likely to adhere  
☐     Somewhat likely to adhere  
☐     Somewhat unlikely to adhere  
☐     Very unlikely to adhere 
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Vignette 4. Mrs. Brown is 65 years old and has had type 2 diabetes for 5 years. Three 
months ago, Mrs. Brown was prescribed Metformin 850 mg (BID), an ACE inhibitor to 
control comorbid hypertension, and a low-dose aspirin. Mrs. Brown currently has a 
HbA1c of 8.5%, a BP of 140/80 mmHg, and a BMI of 29. Her basic metabolic profile is 
normal and GFR > 60. Mrs. Brown reports an intermittent pain in her feet, but has 
difficulty localizing it. There is no history of cardiovascular disease or depression. Mrs. 
Brown has some recent memory loss on formal testing. She lives independently and 
seems to be able to function on her own with only minimal assistance. However, she 
stopped driving, in part because she occasionally got lost, and she no longer 
manages her personal finances. 
 
1. Which anti-hyperglycemic treatment option are you most likely to recommend? Mark 
only one. 
 
☐     Continue Metformin (Glucophage) Monotherapy, Same Dose  
☐     Continue Metformin (Glucophage) Monotherapy, Increase Dose 
☐     Metformin (Glucophage) + Sulfonylurea (Glipizide, Glyburide, Amaryl) 
☐     Metformin (Glucophage) + Thiazolidinedione (Pioglitazone, Actos) 
☐     Metformin (Glucophage) + DPP-4 Inhibitor (Januvia, Onglyza) 
☐     Metformin (Glucophage) + GLP-1 Receptor Agonist (Exentide, Liraglutide) 
☐     Metformin (Glucophage) + Long-Acting Insulin (Lantus, Glargine, Detemir, 
Levemir) 
 
2. How likely is the patient to adhere to your medication recommendations? Mark only one. 
 
☐     Very likely to adhere  
☐     Somewhat likely to adhere  
☐     Somewhat unlikely to adhere  
☐     Very unlikely to adhere 
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Part II. Professional Background 
 
Instructions: Please provide some information about your professional background and practice. 
 
1. What year did you finish your professional education (medical school for physicians)?                       
(Year) 
 
2. What type of clinician are you?  
☐     Family Medicine Physician 
☐     Internal Medicine Physician 
☐     Nurse Practitioner 
☐     Other, Specify:                                                   
 
3. What is the average length of a routine visit in your practice?                   Minutes 
 
4. Approximately what percent of your practice is Medicare? 
☐     < 25% 
☐     25% - 75% 
☐     > 75% 
 
We care about your input. Please use the back of this page to make any final comments about 
how anti-hyperglycemic medication and adherence determinations are made in practice.   
 
Thank you! 
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Appendix B. Sample Approach Email for Leaders of Practice-Based Research Networks 
 
 
Dr. XX, 
 
The rate of hospitalizations for hypoglycemia now exceeds that for hyperglycemia among older 
diabetics. Accepting higher HbA1c levels for older adults with longstanding disease, cognitive 
impairment and multiple comorbidities is the recommendation of the American Geriatrics Society 
and a priority of the Choosing Wisely initiative. Yet, overtreatment is still widespread. 
 
The following scenario study will help your Practice-Based Research Network (PBRN) 
understand how physicians perform to nationally established guidelines and could serve a 
launching point for continuing education around the treatment of older adults with diabetes. We 
are hoping to enroll 250 primary care physicians in this project. 
 
The online questionnaire, sponsored and approved by the University of Minnesota, takes less than 
5 minutes to complete and can be distributed to membership via a common link. Participating 
PBRNs will receive a summary of their results and a comparison of their results to de-identified 
responses from other PBRNs for benchmarking purposes. Responses are anonymous. Specific 
physicians will not be identified to anyone. 
 
A one-page summary of the project and a sample questionnaire are attached to this email. Please 
feel free to contact me with any questions. We look forward to hearing from you. Thank you. 
 
Best,  
 
Ellen McCreedy 
 
PI: Ellen McCreedy 
Doctoral Candidate 
Health Policy and Management 
U of MN School of Public Health 
420 Delaware St SE (MMC 729) 
Minneapolis, MN 55455 
(813) 731-4241 
mccr0184@umn.edu 
  
Sponsor: Robert Kane, MD 
Professor and Minnesota Chair in Long-Term Care and Aging 
Health Policy and Management 
U of MN School of Public Health 
420 Delaware St SE (MMC 729) 
Minneapolis, MN 55455 
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Appendix C. Sample Recruitment Email with Embedded Link to Survey 
 
 
We are inviting you to participate in a survey on diabetic anti-hyperglycemic medication choices 
for older people. This study is being conducted by the University of Minnesota with no external 
funding from any pharmaceutical manufacturer. We are trying to assess the range of approaches 
clincians use in providing care for their patients with diabetes. The survey takes about 4 minutes 
to complete and responses are anonymous.   
  
https://umn.qualtrics.com/SE/?SID=SV_9uEVQQkHqodo5pP 
   
  
For more information, contact:  
  
Ellen McCreedy, PI 
Doctoral Candidate 
Health Policy and Management 
U of MN School of Public Health 
420 Delaware St SE (MMC 729) 
Minneapolis, MN 55455 
mccr0184@umn.edu 
 
Robert Kane, MD, Sponsor 
Professor and Minnesota Chair in Long-Term Care and Aging 
Health Policy and Management 
U of MN School of Public Health 
420 Delaware St SE (MMC 729) 
Minneapolis, MN 55455 
  
Thank you for your time and interest in supporting primary care. 
 
 
 
 
